




DECIPHERING THE SIGNALING MECHANISM OF 





    KIRTHAN SHENOY 






      A THESIS SUBMITTED FOR  
  THE DEGREE OF DOCTOR OF PHILOSOPHY  
              DEPARTMENT OF PHYSIOLOGY 
       NATIONAL UNIVERSITY OF SINGAPORE 
            2012 
i 
 
                              ACKNOWLEDGEMENTS 
As I begin to write this page of my thesis, it suddenly feels like an arduous task to 
express my gratitude in words to those who made my journey through PhD possible 
and memorable. I would firstly like to thank Prof. Shazib Pervaiz, from the 
Department of Physiology, National University of Singapore for being an awesome 
mentor and for all the opportunities I have received under his tutelage. Thank u ‘za 
boss’ for making me a part of your ‘team xtreme’ and for your excellent guidance.  
My gratitude to Jayshree for being there for me as a constant support in every sphere 
of my life in the last 6 years. Jay, I can never thank you enough for all your advice 
and understanding as I saw my share of ups and downs.  Many thanks to Serena and 
Karishma for their friendship. I will always remember those long after-hours in lab 
and I really don’t know who can endure my ever- so- lame jokes more than u both! 
Thank you Chew Hooi, Inthrani and Kartini for helping me with experiments when I 
first joined the lab.  It’s been a pleasure working with Sinong, Gregory and Shi Yuan 
– my LY30 partners; Carolyn, Angeline - my SHEP-1 partners and Agnes – my 
understanding bench-mate! This journey was made memorable in different ways by 
each one of my labmates from the ROS biology & Apoptosis Lab - Thank u all. I 
would also like to extend my appreciation to everybody at the Physiology department 
office, especially Asha, Vasantha and Kumari for their understanding and help. 
As with all endeavors that I have chosen to pursue over the years, I feel fortunate to 
have been supported by my parents throughout my PhD. How can I forget to thank 
my best friends, my brother Karthik, my sis- in- law Kiran and my favourite stress 
buster, my nephew Kavin! As I begin another phase in life, I would like to thank my 
fiancé, Hriday for always listening to my ‘experiment didn’t work’ issues and his 
family for motivating me when I needed it the most. 
ii 
 
             TABLE OF CONTENTS 
 
Acknowledgements                     i 
Table of contents                                ii 
Summary and conceptualization of the study                    x 
List of figures                                 xi 
List of abbreviations                                xiv 
                                                                                            
PART 1 – INTRODUCTION 
1.       THE PROCESS OF TUMORIGENESIS 
1.1       Tumor initiation and promotion                                                                      1 
1.2       Gain-of-function mutation of proto-oncogenes or loss of function  
 mutation of tumor suppressors                                                                        2 
2.       TYPES OF CELL DEATH                                                                                                       4 
2.1       Necrosis                      
2.1.1    Cell death process                      5 
2.1.2    Necrosis inducing agents                                                                                5 
2.2       Autophagy 
2.2.1    The discovery of autophagy and autophagic cell death                                  6 
2.2.2    Proteins important in autophagy                                                                      7 
2.3       Mitotic catastrophe                                                                                          8              8 




2.4.1    Extrinsic or death receptor mediated apoptosis               11 
             2.4.1.1     Ligands and Receptors of the TNF superfamily                            12 
 
  2.4.1.1.1      Tumor Necrosis Factor (TNF) and its cognate   
                      receptors                                                                          13 
       2.4.1.1.2     CD95 ligand and its receptor                                          15 
        2.4.1.1.3     TRAIL (Apo2L) and its cognate receptors                        16 
 2.4.2   Intrinsic or Mitochondria-amplified apoptosis               17 
2.4.2.1     Permeabilization of the mitochondria and release of   
                 apoptogenic factors                                                                         18 
 2.4.2.2    Formation of the apoptosome                19 
 2.4.2.3    Bcl-2 family of proteins in survival and death                               19 
 2.4.2.4    Role of IAP’s                                                                                  21 
 2.4.3   Role of caspases as classical regulators of apoptosis                                     22 
3.       TRAIL RESISTANCE IN CANCER AND THE NEED FOR COMBINATORIAL  
TREATMENTS                                       
3.1       Factors causing resistance to TRAIL-induced apoptosis                                23 
3.1.1    Ratio of surface death to decoy TRAIL receptors                                          24                     
3.1.2    Ratio of c-FLIP to caspase 8                                                                           25 
3.1.3    Upregulation of the anti-apoptotic Bcl-2 and IAP family proteins                25  
3.1.4    PI3-K- Akt, NFκB and MAPK pathways                                                      26 
3.2       Strategies to overcome or enhance sensitivity of cells to TRAIL – small     
 molecule compounds as sensitizers                                                                29 
4.       ROLE OF ROS IN REGULATING SIGNALING PATHWAYS                                         
4.1       Mitochondria as a source of ROS                                                                     31 
4.2       Other sources of intracellular ROS                                                                       31 
iv 
 
4.3       Rationale for scavenging ROS using antioxidants as an approach 
  to tumor therapy                   33                 
4.4       To decrease or not to decrease ROS in tumor therapy?                        34 
4.5       A new approach –understanding the differences in the ROS species 
  produced                                          35 
4.6       Increasing species-specific ROS and pharmacological tailoring of  
 cells as a tumor therapy                                                                                   37 
 
5.       ROS –MEDIATED SIGNALING CHANNELS                                                                     
5.1       Role of H2O2 in the apoptosis signaling pathway                                               39        
5.2       Role of H2O2 in regulating kinases and phosphatases                                    40 
5.3       The MAPK pathway                                                                                       41 
5.3.1   The ERK subfamily                                                                                          
           5.3.1.1   The activators and substrates of ERK                                                42 
           5.3.1.2    Specific interactions of ERK                                                             45 
           5.3.1.3   The ERK - PEA-15 nexus and the role of PKC in  
   regulating MAPKs                                                                                            47 
5.3.2    JNK in stress activated cell death                                                                             49 
5.3.3    p38 in stress-activated cell death                                                                    52 
PART 2 – OBJECTIVE OF STUDY                                                                      54 
PART  3 – MATERIALS AND METHODS 
1.     Cell lines used in the study                                                   56 
2.     Drugs used in the study                                                                                                      57 
v 
 
3.     Phamacological inhibitors and activators used in the study                                     57 
4.    Assessing combinatorial efficacy of the drugs 
 4.1    Determination of cell viability with crystal violet and MTT assay       58 
            4.2   Determination of the tumor cell colony forming ability                              59 
            4.3   Determining the reproliferation potential of cells                                   60 
            4.4   Morphological examination                                                                    60 
5.     Apoptosis related assays 
            5.1   Propidium iodide (PI) staining for DNA fragmentation                         60 
            5.2   Determination of caspase activities                                                        61 
 5.3   Subcellular  - Mitochondrial fractionation                                             62  
6.    Flow cytometric analysis of H2O2 production                                                               62 
7.    Studies to understand the signaling cacade   
7.1   SiRNA-mediated silencing of JNK, ERK and p38                                       63 
 7.2   Analysis of DR4 and DR5 surface expression                                               63 
 7.3  Confocal imaging for PKC α and pERK                                                  64 
7.4   Subcellular - nuclear fractionation                                                           64 
7.5   Detection of signaling proteins by Western blotting                               65 
Appendix: Buffers used for Western Blot analysis 
1.     Protein extraction (obtaining cell lysate)                                                            66 
2.     Measurement of protein concentration                                                                66 
3.     Laemmli loading Buffer                                                                                     67 
vi 
 
4.    Running Buffer                                                                                    67 
5.    Transfer Buffer                                                                                                    67 
6.    TBS                                                                                                                                            67 
7.    Stacking gel preparation                                                                                      68 
8.    Resolving/separating gel preparation                                                                  69 
 
PART 4  - RESULTS 
 
1.  LY30 AUGMENTS THE EFFICACY OF TRAIL IN A SYNERGISTIC  
MANNER AS EVIDENCED BY ENHANCED SENSITIZATON 
1.1       LY30 is a structural analogue of LY29 and is a negative control for    
inhibition of PI3-K enzyme activity                                                               70 
1.2       Preincubation of tumor cells with LY30 enhances TRAIL 
          - induced cell death in tumor cells                                                                    72 
1.3       Synergistic response of SHEP-1 cells when treated with  
           LY30 and TRAIL in combination                                                                   76  
2.   CORROBORATING THE ABILITY OF LY30 TO ACT AS AN EFFICIENT 
SENSITIZER TO TRAIL INDUCED APOPTOSIS 
2.1       Increased DNA fragmentation and morphological changes  
 observed with combined treatment                                                                 79 
2.2       Treatment with LY30 + TRAIL increased caspase activation  
 leading to initiation  of the apoptotic cascade                                                 82 
2.3       Reproliferation potential and colony  forming ability is  
 markedly reduced  following treatment with LY30 and TRAIL                    86 
vii 
 
3.  EVALUATING THE POSSIBLE ROLE OF ROS AS AN UPSTREAM SIGNALING     
MOLECULE 
3.1       LY30 produces ROS in an exposure and time-dependent manner                 89 
3.2       Preincubation of cells with catalase abrogates increase in ROS and 
enhancement of cell death                                                                                            93 
4.  SURMISING THE POSSIBLE DOWNSTREAM SIGNALING CASCADE INITIATED   
BY LY30 
4.1       Increase in expression of activated MAPKs following exposure to  
 LY30 at early time points                                                                                       96 
4.2       MAPK activation by LY30 plays a significant role in augmenting TRAIL- 
            mediated cell death and occurs downstream of H2O2 production                  98 
5.       ASSOCIATING H2O2 PRODUCTION AND ERK REGULATION 
5.1        Activated ERK translocates to the nucleus                                                   100 
5.2       PEA-15 is phosphorylated in a sustained manner and PKC  
            is membrane localized upon treatment with LY30                                          102 
5.3       Understanding the role of PKC and ROS in regulating  
 phosphorylation of PEA-15                                                                            104 
5.4      Silencing PEA-15 sensitizes SHEP-1 cells to TRAIL                                    109 
6.  AFFIRMING DEATH RECEPTOR UPREGULATION AS A MECHANISM FOR 
ENHANCED SENSITIZATION TO TRAIL 
6.1       Efficient execution of TRAIL- induced apoptosis by activation  
 of the extrinsic   pathway is regulated by H2O2                                                                     111 
6.2       Increase in death receptor levels is regulated by H2O2                                                     112 
viii 
 
6.3    Pharmacological inhibition or knockdown of JNK or ERK blocks  
        LY30-induced upregulation of DR4 or DR5 respectively                                  113 
PART 5  - DISCUSSION 
1.       HIGHLIGHTING THE ROLE OF ROS AS A SIGNALING MOLECULE 
1.1       Quercetin – The lead compound of LY29 and LY30                                           124 
1.2       ROS as an initiator of cellular signaling and cell death                                 125 
1.3       Basis for looking at LY30 as a possible ROS producing compound             126 
2.       REGULATION OF MAPK 
2.1       H2O2 as an upstream regulator of MAPK activation                                      127 
2.2       Spatial regulation of ERK by PEA-15                                                            128 
3.       UPREGULATION OF DR4 AND DR5 ALLOWS FOR INCREASED LIGAND BINDING 
3.1       Efficient TRAIL/intrinsic signaling and diminished role of the           
mitochondria/extrinsic pathway                                                                      131 
3.2       Role of ERK and JNK in death receptor upregulation                                   133 
 4.  USE OF TRAIL AS A SINGLE-AGENT TREATMENT OR IN COMBINATION WITH 
OTHER SENSITIZER DRUGS 
4.1       Use of TRAIL as a single-agent or combination treatment option                134 




 4.3     Other proteins targeted by LY30                  138 
5.       REGULATION OF TRAIL RECEPTOR EXPRESSION                                                    138 
6.     NOVEL COMPOUNDS SUCH AS LY30 AS EFFICIENT SENSITIZERS 
6.1       LY30 creates a tipping point that decides the fate of tumor cells                   140 
6.2      Augmented TRAIL signaling activated by novel compounds such                142 
           as LY30 
PART 6-  REFERENCES                                                                                                     145 
APPENDIX                                                                                                                                      177 
1. List of publications 














             SUMMARY AND CONCEPTUALIZATION OF THE STUDY 
Resistance to apoptosis induced by the proapoptotic ligand, TRAIL has dimmed its 
potential as a possible anticancer modality in a clinical setting. Thus, understanding 
mechanisms that contribute to this resistance has been of considerable interest. This 
has also led to the discovery of compounds that can overcome resistance or enhance 
the efficacy of TRAIL in tumor cells. This project has been an effort to understand 
the signaling mechanism of enhanced TRAIL sensitization by one such compound, 
LY303511 in a neuroblastoma cell line, SHEP-1.  Early experimental evidence 
indicated the role of intracellular H2O2 production in activating MAPKs in SHEP-1 
cells. This activated MAPK’s was seen to be an important signal for upregulating 
expression of TRAIL receptors (DR4 and DR5). The resulting increase in availability 
of receptors for ligand (TRAIL) binding at the cell surface allows significant 
amplification of TRAIL-mediated caspase 8 processing, activity and apoptotic cell 
death. The dominance of the extrinsic pathway of apoptosis was indicated by the 
ability of blocking antibodies against DR4 and/or DR5 to completely inhibit LY30-
induced TRAIL sensitization. Pharmacological inhibition and siRNA- mediated gene 
silencing of c-jun N-terminal-kinase (JNK) and extracellular signal-regulated kinase 
(ERK) inhibited LY30-induced increase in surface expression of DR4 and DR5, 
respectively. In addition, the role played by the phosphoprotein, PEA-15 in 
regulating intracellular localization of activated ERK could be important in directing 
the signaling cascade and biological outcome.  Elucidating the possible mechanism 
of action of LY30 holds implications for the use of LY30 and other similar 
compounds for enhancing the apoptotic sensitivity of neuroblastoma cells that often 
become resistant to TRAIL and refractory to chemotherapy.  
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PART 1- INTRODUCTION 
 
 
1.   THE PROCESS OF TUMORIGENESIS 
 
 
1.1 TUMOR INITIATION AND PROMOTION 
The term „tumor initiation‟ refers to a gradual process of oncogenesis (used 
interchangeably with tumorigenesis or carcinogenesis) during which a normal cell 
undergoes transformation into a cancerous cell (Fearon, 1997). It is largely 
understood to be a result of a loss of homeostatic balance between cell growth and 
cell death leading to unregulated cell division. During this process, a cell acquires 
characteristics such as self-sufficiency in growth signals; increased angiogenesis; 
enhanced metastasis and an ability to override apoptotic signals (Hanahan & 
Weinberg, 2000). These acquired properties allow transformed cells to grow in an 
uncontrolled manner with a limitless replication potential. Susceptibility to cancer 
can either be inherited wherein a genetic predisposition due to familial mutations can 
increase the chance of cancer or can be acquired by exposure to carcinogens/ 
mutagens (Hodgson, 2008). 
 
Carcinogen as a term refers to substances that can initiate carcinogenesis or increase 
susceptibility to cancer. They include environmental toxins, hormones or dietary 
factors, most of which can induce genotoxic stress and mutagenesis (Fung et al., 
1993; Huff, 2010). Thus, an inherited or acquired mutation which include point 
mutations, chromosomal translocations, gene rearrangements, insertions and 
deletions play an important role in tumor initiation and progression. The most studied 
mutations that initiate tumorigenesis include gain-of-function mutation of a proto-
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oncogene or a loss-of-function mutation of a tumor suppressor gene (Hogg et al, 
1993; Stehr et al, 2011). Once a tumor has been initiated, the process of tumor 
progression is a result of successive mutations that increase the stage or severity of 
cancer. Progression of a tumor is associated with cumulative effects such as 
neoplasia and a clonal expansion of cells allowing cancer cells to undergo somatic 
evolution. Therefore, a mutation of an oncogene could progressively target a tumor 
suppressor and so on, thereby completely eliminating any possible regulation or 
control of the cell cycle.  
1.2 GAIN-OF-FUNCTION MUTATION OF PROTO-ONCOGENES OR LOSS OF 
FUNCTION MUTATION OF TUMOR SUPPRESSORS  
Proto-oncogenes are important signal transducers for cell division, cell growth and 
cell differentiation and are susceptible to mutation. When a proto-oncogene 
undergoes mutation, it is termed as an oncogene and its protein product is an 
oncoprotein. Considering the functional role of proto-oncogenes in a cell, the gain-
of-function mutation resulting in a constitutively active/overexpressed oncogene or 
overactive oncoprotein allows abnormal cell division and/or uncontrolled growth of 
cancer cells (Croce, 2008).  
 
The most widely studied proto-oncogenes include members of the Receptor Tyrosine 
Kinase family; Serine/threonine kinases, regulatory G proteins and transcription 
factors that signal for cell growth or regulate the cell cycle. When a proto-oncogene 
is a cell surface growth factor receptor of the Receptor Tyrosine Kinase family such 
as EGFR (Epidermal Growth Factor Receptor) or VEGFR (Vascular Endothelial 
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Growth Factor Receptor), an overexpression of it would mean an increased number 
of receptors to which the ligand (growth factors) can bind to and thereby promote 
growth and angiogenesis (Pawson & Warner, 2007). Linking these receptors to 
downstream signaling are regulatory G proteins such as Ras which can also be 
mutated to become an oncogenes (Bos, 1989; Rodenhuis & Slebos, 1990). 
Dependency on oncogenic Ras as a survival advantage has been reported in many 
cancers and has been shown to be an important target of many- a- cancer drugs that 
take the approach of hitting oncogenic addiction of cancer cells (Sharma & 
Settleman, 2007). In addition, proto-oncogenes that are involved in regulating the 
cell cycle progression are also frequently mutated which include serine/threonine 
kinases such as cyclin-dependent kinases (cdk‟s) and their regulatory protein cyclins. 
They together control the transit to and from different cell cycle phases and thus any 
alteration in their functioning can lead to unregulated growth of cells. In addition to 
regulating numerous other direct and indirect targets that aid cell growth, constitutive 
expression of the widely studied transcription factor c-myc controls cell proliferation 
via regulating cyclins (Battey et al, 1983; Deshpande et al, 2005). 
 
On the other hand, tumor suppressor genes control the crucial cellular function of 
inhibiting proliferation of cells that are not genetically stable. Tumor suppressor 
genes are mainly activated upon sensing DNA damage. Depending on the extent of 
damage, they perform the function of halting the cell cycle to either initiate a repair 
mechanism or to induce cell death. Examples of well studied tumor suppressors 
include protein products of the p53 and Retinoblastoma (Rb) gene (Lin et al, 1996; 
Mattar et al, 2004).  Thus, any mutation of tumor suppressor genes leading to its 
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inactivation causes abrogation of efficient checkpoints in the cell cycle and evasion 
of apoptotic signals allowing uncontrolled growth of cells in an accelerated fashion.  
The importance of p53 as a „genome guard‟ has been studied over the years and it is 
now understood that the cellular localization of p53 is an important determinant of its 
exact function (Liang & Clarke, 2001). In addition to the transcription-independent 
role of p53 at the cytosol and its subsequent translocation to the mitochondria to 
initiate cell death mechanisms, the main role of p53 is in the nucleus and is that of a 
potent transcription factor which regulates its downstream effector target proteins 
such as cell cycle regulators, DNA repair proteins and several pro-apoptotic proteins.  
 
2.   TYPES OF CELL DEATH   
 
 
The process of tumorigenesis involves loss of balance between cell growth and cell 
death.  As we garner knowledge of the various mechanisms of growth signaling that 
aid transformation and provide a survival advantage to tumor cells, a parallel stream 
of study has focussed on understanding the mechanisms by which a cancer cell could 
die and how it evades cell death. Cell death processes are broadly classified as 
programmed cell death pathways that include apoptosis and autophagy and the non-
programmed cell death pathways that include necrosis and mitotic catastrophe. As 
we progress towards better understanding of cell death pathways, newer mechanisms 
such as programmed necrosis are being discovered. However, the challenge is to 
clearly understand these cell death signaling networks and to preempt the mechanism 
by which cancer cells could evade it. Harnessing this information will be useful in 




2.1   NECROSIS 
 
2.1.1   The cell death process 
 
In an effort to explain the process by which execution of cell death occurs by 
necrosis, the initial studies focussed on elucidating biochemical differences between 
apoptosis and necrosis.  Necrosis has been generally described as a passive and 
accidental form of cell death and was highlighted as a way of cell demise that is not 
orderly (Trump et al, 1997). However, there are a lot of recent reports clearing some 
of our misconceptions of necrosis and introducing new concepts such as programmed 
necrosis or necroptosis (Hitomi et al, 2008).  The pivotal role of Receptor Interacting 
Protein (RIP) interacting with FADD and caspase 8 leading to activation of proteins 
such as JNK has been highlighted in a number of studies. The subsequent activation 
of calpain (calcium-dependent, non-lysosomal cysteine proteases) activation and 
mitochondrial collapse has been shown to be integral for necroptosis to occur 
(Declercq et al, 2009; Festjens et al, 2007; Zhang et al, 2009). Also, it has been 
shown that the components of the extrinsic pathway of apoptosis can infact inhibit 
RIP1 mediated necroptosis (Osborn et al, 2010). Alternatively, a possible switch 
towards programmed necrosis when apoptosis or autophagy is inhibited has been 
suggested (Scheller et al, 2006).This indicates an interesting cross-talk between these 
two modes of cell death. 
 
2.1.2   Necrosis inducing agents  
 
Necrosis, a more spontaneous process as compared to necroptosis can be induced by 
stress signals such as disrupted ATP production or due to enormous oxidative stress 
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in cells (Leist et al, 1997; Suematsu et al, 2003). The non-physiological levels of 
ROS, especially that of hydroxyl radical, has been shown to cause lipid peroxidation 
and DNA damage. In addition, calcium and oxidative stress induced 
permeabilization of the plasma membrane and membranes of intracellular organelles 
have been suggested to be initiators of necrosis. On the other hand, necroptosis is a 
relatively programmed process that is activated by Receptor Interacting Protein (RIP) 
and has been shown to be initiated by death receptor ligands like TNF-α, FasL and 
TRAIL or due to loss of intracellular ionic balance of calcium and consequent 
activation of calcium-activated calpains (Holler et al, 2000). 
 
2.2   AUTOPHAGY 
 
2.2.1   The discovery of autophagy and autophagic cell death 
 
Autophagy was discovered as an important process by which eukaryotic cells 
respond to starvation (Mortimore & Poso, 1987).  It is mainly understood to be a  
process of programmed self-destruction where engulfment of damaged cytosolic 
organelles and long-lived proteins allow formation of double-membrane vesicles 
called phagophore which then expands to form the autophagy vacuole or 
autophagosome (Levine & Klionsky, 2004; Mizushima & Klionsky, 2007). The 
proteins devoured in the autophagosome are largely non-selective and are delivered 
via fusing to the lysosomes, an organelle that contains acid hydrolases, to breakdown 
cellular material (Lockshin & Zakeri, 2002). Thus, autophagic flux ends with the 
lysosomal hydrolases degrading these macromolecules to yield amino acids which 




The role of autophagy in tumor cells is a double-edged sword and our concepts are 
constantly being restructured based on new findings. Apart from the first studied role 
as a mechanism for survival and adaptive proliferation in tumor cells, a lot of 
attention is now being given to understand its role as a form of cell death in tumor 
cells (Degenhardt et al, 2006; Jin & White, 2007; Yu et al, 2004).  An extensive 
study by (Yu et al, 2004) showed that the consequence of inhibiting the apoptotic 
form of cell death by down regulating caspase 8 or by using a pan-caspase inhibitor 
Z-VAD is induction of cell death characterized by vacuole formation. This form of 
cell death was shown to be autophagy as it could be inhibited by using an autophagy 
inhibitor or by downregulating proteins shown to be important in autophagic cell 
death.   
 
2.2.2     Proteins important in autophagy 
 
The observation that inhibitors to an important nutrient (amino acid and growth 
factor) signaling cascade, mTOR could inhibit autophagy revealed its role in 
autophagy. Other proteins regulating autophagy were soon discovered and mainly 
included AMP-activated protein kinase (AMPK) (Shang & Wang, 2011);   FADD 
(Thorburn et al, 2005) and TRAIL (Mills et al, 2004). Apart from these, proteins 
dedicated to regulating autophagosome formation and autophagy include the 
autophagy-related (Atg) proteins - Atg1–10, Atg12–14, Atg16–18, Atg29, and Atg31 
(Klionsky et al, 2007). One important Atg protein is Atg6 or Beclin 1 (Bcl-2 
interacting coiled-coil protein), which along with its binding patner Vps34 plays a 
lead role in initiating autophagosome formation. In addition, Beclin 1 also interacts 
with the anti-apoptotic protein Bcl-2 and a reduced interaction upon starvation allows 
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progression of the canonical Beclin 1 dependent autophagy (Liang et al, 1998; 
Pattingre et al, 2005). Also, Beclin 1 has been shown to form a complex with another 
protein called UVRAG (UV irradiation resistance-associated gene) that acts as a 
tumor suppressor to induce autophagic cell death (Liang et al, 2006). Interestingly, 
signaling molecules such as Reactive Oxygen Species (ROS) and Ca
2+
 have also 
been shown to play an important role in autophagic cell death  (Azad et al, 2009; 
Scherz-Shouval et al, 2007) (Hoyer-Hansen & Jaattela, 2007) . Also, recent studies 
have looked at the possibility of a crosstalk between the autophagic and apoptotic 
cell death processes. These reports suggest that the two forms of cell death are 
activated in parallel and that the prevailing intracellular signaling conditions 
determine the switch in the mode of cell death (Djavaheri-Mergny et al, 2010; Maiuri 
et al, 2007; Wong et al, 2010). 
 
2.3   MITOTIC CATASTROPHE 
 
Cell death by mitotic catastrophe is essential to counteract cells from becoming 
genetically unstable and thereby prevent them from undergoing transformation to a 
cancerous cell.  The term „mitotic-incompetence‟ has been used to describe cells 
which have aberrant segregation of chromosomes that accumulate DNA damage and 
thus causing inhibition of cell progression through the cell cycle (Vitale et al, 2011). 
Since mitotic catastrophe largely results from deregulated cell cycle checkpoints, 
pharmacological inhibition or silencing of any of the cell cycle checkpoint regulators 
such as ATM, ATR and polo-like kinases would be able to induce mitotic 
catastrophe in cells (Cogswell et al, 2000; Roninson et al, 2001). In addition, agents 
that induce DNA damage, microtubule-hyperpolymerisation or microtubule-
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depolymerization can cause a similar effect. Indeed, some studies indicate it as a 
specialized form of apoptosis due to the involvement of caspases and mitochondrial 
compromise (Castedo et al, 2004) while some other studies show that this form of 
cell death is different from apoptosis as it can be enhanced by over expression of 
antiapoptotic Bcl-2 family proteins. In addition, since mitotic catastrophe cannot be 
rescued by caspase inhibition following treatment with spindle poisons, it is seen to 
be different from the apoptotic form of cell death (Lock & Stribinskiene, 1996; 
Nabha et al, 2002). Despite the comparision, apoptosis and mitotic catastrophe can 
be seen as two parallel events that a tumor cell needs to evade in order to survive as a 
mitotically incompetent cell. Drugs such as Vincristine and Curcumin have been 
noted for their ability to damage the mitotic spindle, induce multiple micronuclei 
formation and introduce mitotic catastrophe in apoptotis resistant HL-60-derived 
human promyelocytic leukemia cell line, HCW-2 cells (Magalska et al, 2006; 
Mansilla et al, 2006). 
2.4   APOPTOSIS  
 
 
The term „apoptosis‟ literally means falling off and was coined to suggest a cell 
involved in self-destruction or committing suicide. Apoptosis is biochemically and 
morphologically characterized as a programmed form of cell death which follows an 
orderly cascade of events (Hengartner, 2000).  Some of the classical hallmarks of 
cells undergoing apoptosis are chromosomal DNA fragmentation, membrane 
blebbing, chromatin condensation and cell shrinkage (Saraste & Pulkki, 2000). 





        
  Figure 1: Pathways of apoptosis  
The two main pathways of apoptosis, the extrinsic and the 
intrinsic pathway, are activated by ligation of the death receptors 
or due to factors that induce DNA damage. (Carlo-Stella C. et al. 





evasion of apoptosis is infact one of the best known characteristic of cancer cells 
(Hanahan & Weinberg, 2000). Execution of apoptosis can be mediated by the death 
receptors of the extrinsic cell death pathway or might involve the mitochondria in the 
intrinsic cell death pathway. Although, tumor cells have been shown to undergo non-
classical apoptosis by the nuclear translocation of the mitochondrial flavoprotein 
Apoptosis-inducing Factor (AIF) (Akematsu & Endoh, 2010), the central role played 
by caspases in both the extrinsic and intrinsic pathway is of prime importance and is 
the focus of most studies on apoptosis.  
 
2.4.1   EXTRINSIC OR DEATH- RECEPTOR MEDIATED APOPTOSIS    
 
 
The extrinsic pathway of apoptosis is initiated at the cell membrane by the binding of 
a ligand to the extracellular region of its cognate death receptor, allowing for a 
conformational change in these receptors. This change in conformation leads to 
recruitment of adapter proteins which binds to the death receptors via their Death 
Domains (DD‟s).  The proximity and association of proteins forms a multimeric 
complex called the Death-Induced Signaling Complex (DISC) in the lipid-enriched 
microdomains or lipid rafts, to initiate activation of the caspase cascade. Upon 
apoptotic trigger, an efficient DISC assembly followed by robust activation of 
caspase 8 suffices to activate downstream effector caspases such as caspase 3, 
thereby leading to apoptosis in some cell types (Sprick et al, 2000). Such cells, which 
are categorised as Type 1 cells, execute apoptosis independent of the mitochondria 




When the amount of caspase 8 activated is not sufficient to drive the cells towards 
apoptosis, it signals for the mitochondria to act as an apoptosis amplification loop.   
In this case, the activated caspase 8 cleaves Bid to truncated Bid (tbid) which 
undergoes post-translational modifications to translocate to the mitochondria and 
interacts with pro-apoptotic members of the Bcl-2 family. This interaction promotes 
mitochondrial outer membrane permeabilization (MOMP) causing a drop in the 
mitochondrial transmembrane potential ( m), leading to the release of apoptogenic 
factors from the mitochondria, thereby enhancing apoptosis in Type 2 cells (Ozoren 
& El-Deiry, 2002). 
 
2.4.1.1    Ligands and Receptors of the TNF superfamily 
 
 
The ligands and receptors belonging to the TNF receptor superfamily are cytokines 
that are transmembrane proteins. A 150 amino acid core region is structurally 
conserved in most members of the TNF superfamily of ligands. Cleavage of many 
members of the TNF superfamily of ligands at their extracellular carboxy-terminal 
region by specific metalloproteinases yields soluble ligands which are arranged and 
stabilized as trimers, usually homotrimers. Interestingly, studies indicate that the 
apoptosis inducing potential of some TNF ligands is lower than that of the 
membrane-bound form following proteolytic cleavage (Schneider et al, 1998).  The 
best studied members of the TNF ligand superfamily mainly include TNF-related 
apoptosis-inducing ligand (TRAIL), CD95L (FasL), RANKL (OPGL) and TNF.  
 
The ligands of the TNF receptor superfamily bind to its cognate receptors which also 
belong to the same superfamily. The presence of a Cysteine Rich Domain (CRD) is 
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responsible for the ligand binding specificity (Marsters et al, 1992; Orlinick et al, 
1997). Eight members of the TNF receptor superfamily that signal for cell death that 
have been characterized so far include TNF R1 (DR1, CD120a); CD95 (DR2, APO-
1, Fas); DR3 (also known as APO-3, LARD, TRAMP); TRAIL R1(DR4, APO-2); 
TRAILR2(DR5, KILLER and TRICK2); DR6; ectodysplasin A receptor (EDAR) 
and nerve growth factor receptor (NGFR), which contain the characteristic death 
domain (DD) in their cytoplasmic region. The other receptors studied in this 
superfamily are called decoy receptors (DcR‟s) and they include TRAILR3 (DcR1), 
TRAILR4 (DcR2), DcR3 and osteoprotegrin (OPG, RANK) (Degli-Esposti et al, 
1997). These decoy receptors either contain a truncated version of the DD or do not 
contain the DD and hence cannot transduce apoptotic signals.  
 
In addition to the known concept of ligand binding - dependent receptor trimerization 
which activates the downstream signaling apoptotic cascade, studies have shown that 
TNFR, Fas and DR4 exist as preassembled receptors. This preassembly of receptors 
is facilitated by the existence of an extracellular domain called pre-ligand-binding 
assembly domain (PLAD) and allows oligomerization, probably trimerization of the 
receptors independent of ligand binding (Chan et al, 2000; Golstein, 2000; Siegel et 
al, 2000). 
 
2.4.1.1.1   Tumor Necrosis Factor (TNF) and its cognate receptors 
 
The role of TNF-TNFR in cell signaling is complex and the exact mechanisms are 
still being studied. This receptor-ligand complex plays diverse roles in cells of 
different types and also within each cell type. Its role in activating multiple signaling 
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networks that can either induce an inflammatory response, cell proliferation or cell 
death has been extensively reported (Kuwano & Hara, 2000). The ligand TNF binds 
two receptors namely TNFR1 and TNFR2 at the extracellular ligand binding N-
terminal region with high affinity. Contrary to TNFR2 which does not contain a 
death domain, TNFR1 is a death domain containing receptor and hence binding of 
the ligand to the receptor leads to recruitment of adapter proteins such as TRADD, 
FADD, TRAF2 and/or RIP which interact with each other via their DD. 
 
Depending on whether or not the adapter protein is recruited and the death signaling 
cascade is initiated, the cellular response largely varies between apoptosis and 
inflammation. There are several studies on TNF and hence, listed here are only a few 
of the many mechanistic explanations of TNF signaling. Complexing of the ligand-
receptor with TRADD leads to further interaction with TRAF2. This complex then 
binds to the autophosphorylated and the polyubiquitinated form of RIP to assemble a 
multi-protein complex signaling for inflammation and survival via efficient 
activation of NF-κB (Jackson-Bernitsas et al, 2007). Alternatively, this complex can 
also activate the JNK and p38 MAPKs that have been shown to play an active part in 
mediating TNF- induced apoptosis (Wicovsky et al, 2007). Constant attempts to 
inhibit JNK-initiated apoptotic signaling by downstream targets of NF-κB such as 
XIAP and c-FLIP has also been elucidated (Wullaert et al, 2006). On the other hand, 
deubiquitinated RIP allows TRADD to recruit FADD to this complex whose DD is 
unoccupied and is free to interact with the DD of caspase 8 leading to activation of 
caspase 8 and enhanced apoptosis. Furthermore, RIP1 itself is a substrate of caspase 
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8 that can further cleave RIP and allow apoptotic execution to proceed (Micheau & 
Tschopp, 2003; Wang et al, 1998). 
 
 2.4.1.1.2    CD95 ligand and its receptor 
 
The CD95 or Fas (Fibroblast-associated) receptor is an unbiquitously expressed Type 
1 transmembrane protein abundant in hepatocytes, epithelial cells and activated 
mature lymphocytes. The negative regulation of the membrane-bound form by the 
soluble form obtained by alternative splicing has been reported (Cascino et al, 1995; 
Cheng et al, 1994).  On the other hand, its natural ligand is FasL which is a Type 2 
transmembrane protein and is present both in its membrane-bound and soluble form. 
Loss of activity is observed in the soluble form obtained by proteolytic cleavage of 
the ligand by serine proteases such as Matrix Metalloproteinases (MMP-7) (Powell et 
al, 1999; Tanaka et al, 1998). 
 
A few interesting recent studies on the Fas/FasL signaling pathway have shown that 
localization to the lipid rafts and palmitoylation at the cytoplasmic region of the Fas 
receptor is required for efficient Fas signaling (Chakrabandhu et al, 2007; Feig et al, 
2007; Legembre et al, 2006). In addition, it has been observed that following ligand 
binding and recruitment of the adapter protein FADD, there is  formation of large 
signaling protein oligomerization structures (SPOTS) (Siegel et al, 2004) which aids 
recruitment of pro-caspase 8 leading to activation of caspase 8 via „induced 
proximity‟ mediated auto-cleavage (Algeciras-Schimnich et al, 2002). This has been 
shown to be a requirement for efficient DISC assembly followed by execution of 
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apoptosis.  Interestingly, a few isolated studies have been able to show that RIP can 
also bind to the DD of FasR, thereby activating caspase 2 and inducing apoptosis. 
 
2.4.1.1.3   TRAIL (Apo2L) and its cognate receptors 
 
The discovery of TRAIL heralded a number of studies on targeted anticancer therapy 
using proapoptotic ligands. Although the sequence homology of TRAIL with FasL 
and TNF is not significantly high, the observation that the crystal structure of TRAIL 
is highly homologous to the 3D structure of other TNF family ligands is interesting 
to note (Cha et al, 1999; Pitti et al, 1996; Wiley et al, 1995). Like most other ligands 
of the TNF superfamily, TRAIL is a type 2 transmembrane protein which can be 
cleaved at its C terminal region to obtain the soluble form.  
 
The most notable aspect of TRAIL for use as an efficient anti-tumor agent stems 
from the studies showing that TRAIL targets cancer cells more selectively as 
compared to normal cells (Ashkenazi et al, 2008; Steele et al, 2006; Walczak et al, 
1999). In addition, the encouraging statistics from preclinical and clinical studies of 
TRAIL on non-human primates reinforces the hope that TRAIL is indeed as 
promising as it was initially observed to be (Ashkenazi et al, 1999; Daniels et al, 
2005). 
 
Since its discovery in 1995, efforts to obtain recombinant TRAIL was successful to a 
certain extent but was hindered by misconceptions that a form of recombinant 
TRAIL had severe side effects due to its hepatotoxicity (Ganten et al, 2006; Jo et al, 
2000). This was clarified by follow-up studies attributing the cause of hepatotoxicity 
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to the exogenous/recombinant tag such as polyhistidine which affected its tertiary 
structure and hence its function (Lawrence et al, 2001). TRAIL can bind to mainly 
four of its cognate receptors. The two death receptors namely DR4 (TRAIL R1) and 
DR5 (TRAIL R2) contain the canonical DD in their cytoplasmic region which allows 
for binding to docking proteins such as FADD and subsequent activation of caspase 
8 or 10 at the DISC (Pan et al, 1997). The two decoy receptors are DcR1 (TRAIL 
R3) and DcR2 (TRAIL R4) which are unable to transduce apoptotic signals as they 
either contain a truncated version of the DD or do not contain the DD (Marsters et al, 
1997; Sheridan et al, 1997). They are seen to be frequently upregulated in cancers as 
they compete with the death receptors for ligand binding and hence act as nullifiers 
of TRAIL-apoptotic signal. TRAIL can also bind to another soluble receptor called 
Osteoprotegerin (OPG, RANK) (Emery et al, 1998). However, the binding is not of 
high affinity and the function of this interaction is not convincingly elucidated. 
 
2.4.2   INTRINSIC OR MITOCHONDRIA-AMPLIFIED APOPTOSIS 
 
The differences between cell types in their ability to undergo apoptosis either 
independent of the mitochondria by inducing robust activation of caspase 8 or by 
requiring an apoptosis-amplification via the mitochondria, led to classification of the 
characteristic Type 1 or Type 2 cells as introduced earlier. The involvement of 
mitochondria in apoptosis was discovered by the serendipitous observation that 
preapoptotic peripheral T lymphocytes incorporated the dye, DiOC6 to a lesser extent 
as compared to healthy viable cells, indicating a loss of mitochondrial 
transmembrane potential ( m) in cells undergoing apoptosis. The subsequent 
studies showed that the drop in membrane potential is an irreversible commitment to 
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apoptosis and that it is regulated by the Bcl-2 family of proteins (Newmeyer et al, 
1994; Zamzami et al, 1995). 
 
 2.4.2.1   Permeabilization of the mitochondria and release of apoptogenic factors  
 
Channels known as Permeability Transition pore (PTP) connect the outer to inner 
mitochondrial membranes and comprise of adenine nucleotide translocator (ANT), 
peripheral benzodiazepine receptor, Cyclophilin D and the voltage-dependent anion 
channel (VDAC) (Marzo et al, 1998b). In a healthy viable cell, the mitochondria 
utilizes substrates to form a proton gradient across the mitochondrial membrane 
keeping the PTP mostly closed. However, an upstream stress signal or proapoptotic 
stimuli can lead to fluctuations in voltage that is sensed by the PTP leading to its 
opening. This triggers a chain of events that starts with entry of small molecules of 
low molecular weight in to the mitochondria. The effect of this is swelling of the 
mitochondria and a sudden increase in the permeability of the mitochondrial inner 
membrane (mitochondrial permeability transition). In addition, the mitochondrial 
outer membrane permeabilization (MOMP) can occur via the PTP with or without 
the involvement of proapoptotic members of the Bcl-2 family members such as Bak 
and Bax (Marzo et al, 1998a; Shimizu et al, 1999). Consequently, this leads to 
depolarization of the mitochondria and dissipation of the mitochondrial 
transmembrane potential ( m) (Kroemer et al, 2007).  
 
A consequence of MOMP is the release of various apoptogenic factors from the 
mitochondrial inter-membrane space (IMS) into the cytosol. The majority of 
Cytochrome c (cyt c) is bound to cardiolipin in the mitochondrial inner membrane 
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and is released into the cytosol upon apoptotic stimuli. The release of second 
mitochondria-derived activator of caspases/direct inhibitor of apoptosis-binding 
protein with low pI (Smac/DIABLO) allows the cell to combat any resistance to 
apoptosis exerted by the Inhibitor of Apoptosis Proteins (IAP) family members such 
as XIAP and survivin as introduced in the following sections (Du et al, 2000). 
 
 2.4.2.2   Formation of the apoptosome 
 
The apoptosome is a large complex of proteins which acts as a molecular platform 
whose formation is initiated by the release of cyt c from the mitochondria. Apoptotic 
protease activating factor 1 (Apaf1) is a monomeric cytosolic protein which contains 
caspase activation and recruitment domain (CARD), an ATPase domain bound to 
ADP that keeps Apaf1 in an inactive state and WD40 repeat domains. The released 
cyt c binds to Apaf1 at its WD40 repeat domain which allows binding of ATP to this 
complex (Liu et al, 1996). Binding of ATP exposes the CARD of Apaf1 leading to 
recruitment and binding of pro-caspase 9 to the complex via the CARD, thereby 
facilitating its catalytic maturation and activation. Activation of caspase 9 leads to 
subsequent activation of effector caspases and initiation of the apoptotic cascade (Li 
et al, 1997a). 
 
2.4.2.3     Bcl-2 family of proteins in survival and death 
 
The Bcl-2 (B-cell lymphoma 2) family of proteins play a central role in the release of 
factors aiding apoptosis from the mitochondria (Letai et al, 2002; Tsujimoto & 
Shimizu, 2000). All members of this family of proteins contain the characteristic 
Bcl-2 homology (BH) regions and can be either pro or anti apoptotic (Letai et al, 
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2002). Based on this structural and functional aspect, the large number of proteins 
belonging to this family are classified in to 3 subfamilies namely the anti-apoptotic 
proteins such as Bcl-2, Bcl-xL, Bcl-w, Mcl-1 and A1, which contain sequence 
homology between BH1 to BH4; multidomain pro-apoptotic proteins such as Bax, 
Bak and Bok which contain homology between BH1 to BH3; BH3-only proapoptotic 
proteins such as Bik, Bad, Bid, Bim, Noxa, Bnip3 and Puma which only show 
sequence homology at BH3 (Adams & Cory, 1998; Martinou & Green, 2001). 
 
The anti-apoptotic proteins of the family have localized functions at different 
intracellular locations. Presence at either the outer mitochondrial membrane, at the 
membrane of endoplasmic reticulum (ER) or at the nuclear membrane, prevents 
execution of apoptosis. The multidomain proapoptotic proteins are mostly redundant 
in function. Bax and Bak are both cytosolic proteins that have also been shown to 
play a role at the ER in regulating apoptosis. Both Bax and Bak are kept sequestered 
in the cytosol in the absence of any trigger. However, upon receiving apoptotic 
stimuli, these proteins translocate to the mitochondria and integrate in to 
mitochondrial membrane. At the membrane, Bax and Bak can form multimers which 
cause MOMP, thus allowing release of apoptogenic proteins from the mitochondria.  
 
This activation of Bax and Bak is regulated by the BH3-only pro-apoptotic proteins 
which are mostly localized in the cytosol (Puthalakath & Strasser, 2002). Proteins 
such as Bid, Bad and Bim act as sensors of death signal and undergo modifications to 
be translocated to the mitochondria (Luo et al, 1998).  At the mitochondria, some 
proteins of this family can interact with proteins such as Bcl-2 and nullify its 
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antiapoptotic effect. The role of caspase 8 in cleaving Bid to form tBid (truncated 
Bid) that can localize to the mitochondria and act as a direct amplifier of apoptosis 
signaling is well-studied (Li et al, 1998b). Similarly, an apoptotic signal allows for 
Bad dephosphorylation which then translocates to the mitochondria to 
heterodimerize with anti-apoptotic proteins of this family, allowing multidomain 
proapoptotic proteins to execute apoptosis.  
 
2.4.2.4    Role of IAP’S 
 
The Inhibitor of Apoptosis Protein (IAP) family was first discovered in 
Baculoviruses as a negative regulator of apoptosis (Crook et al, 1993; Duckett et al, 
1996). The six IAP‟s identified so far include cellular-IAP1 (c-IAP1) or HIAP-2, 
cellular-IAP2 (c-IAP2) or HIAP-1, X-linked IAP (XIAP) or hILP, NAIP, Survivin 
and BRUCE (Ambrosini et al, 1998; Duckett et al, 1996). Proteins belonging to this 
family contain one to three copies of a conserved 70 amino acid stretch called the 
Baculoviral IAP repeat (BIR) which is crucial for its functioning.  
 
In addition, some IAP‟s also contain a RING domain near the carboxy-terminal 
which has been shown to aid in inhibiting apoptotic signaling.  However, it has also 
been shown that the presence of the RING domain is dispensable as the presence of 
BIR domain has been shown to be sufficient for inhibiting apoptosis (Vucic et al, 
1998). The human c-IAP1 and c-IAP2 proteins contain the CARD between the BIR 
and RING domains. Similar to the RING domain, absence of this domain allows c-
IAP‟s to retain their apoptosis inhibiting ability. Supression of TNF, Fas and 
Etoposide mediated apoptosis is seen when XIAP, c-IAP1, c-IAP2 or Survivin is 
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overexpressed (Li et al, 1998a). Evidence of inhibition of caspase activation upon 
binding of XIAP, c-IAP1, and c-IAP2 to specifically, caspases 3, 7, and 9 has been 
shown (Roy et al, 1997). Physical interaction of survivin with caspases 3, 7, and 9 
was also observed reinforcing that IAP‟s indeed are endogenous caspase inhibitors 
that can blunt apoptotic signaling cascades (Tamm et al, 1998). 
 
2.4.3   ROLE OF CASPASES AS CLASSICAL REGULATORS OF APOPTOSIS 
 
Caspases belong to the interleukin-1β-converting enzyme (ICE) family and are 
present in their inactive form as zymogens (procaspases) in cells. The 14 isoforms of 
caspases identified so far contain a conservative pentapeptide active site „QACXG‟ 
(where X can be R, Q or D). The role of caspases (cysteine proteases cleaving after 
Aspartate) in controlling apoptosis execution is crucial for orderly killing of tumor 
cells and in physiological development. Additionally, some caspases have been 
shown to play a role in inflammation and immune response. Based on their function, 
caspases are classified as initiator caspases (Caspase - 2, Caspase - 8, Caspase - 9, 
and Caspase - 10); executioner caspases (Caspase - 3, Caspase - 6 and Caspase - 7) 
and inflammatory mediators (caspase - 1, 4, 5, 11 and 12) (Fan et al, 2005).  
 
An upstream apoptotic stimulus can signal for a shutdown of intracellular regulatory 
processes allowing breakdown of the cell in a systematic manner. Programmed cell 
death (PCD) or cell suicide ends in engulfment of the apoptotic cell by phagocytic 
cells. This process ascertains that cells that have completed their lifespan or those 
that are damaged are „neatly‟ eliminated without affecting the tissue integrity. The 
initiator casapases such as caspase -8 and -10 contain long prodomains called 
23 
 
procaspases which contain the death effector domain (DED) while initiator caspases 
-2 and -9 contain the caspase recruitment domain (CARD) (Fesik, 2000). The 
activation of caspases is explained by the „induced proximity‟ hypothesis which 
suggests auto-activation when a large number of these apical caspases are in 
proximity. More detailed activation by forming of stable dimeric intermediates in 
case of caspase 8 or by Apaf-1 mediated oligomerization of caspase 9 has been 
studied. This leads to further activation of effector caspases, thus initiating a caspase 
cascade leading to apoptosis (Jin & El-Deiry, 2005).  
 
Execution of apoptosis involves action of these proteases on polypeptide chains of its 
substrate proteins, thus inducing apoptotic characteristics and hallmarks. The 
substrate specificity is determined by the presence of different evolutionary 
conserved cleavage sites, leading to substrate preference or specificity. For example, 
caspase 3 and caspase 7 more specifically cleave and inactivate a protein 
participating in DNA repair called PARP (Poly (ADP-ribose) polymerase), while 
caspase 6 cleaves structural nuclear protein such as lamin A. 
 
3.    TRAIL RESISTANCE IN CANCER AND THE NEED FOR COMBINATORIAL 
TREATMENTS 
 
3.1   FACTORS CAUSING RESISTANCE TO TRAIL-INDUCED APOPTOSIS 
 
Despite the promising decline in viability of a panel of tumor cells and favourable 
clinical data indicating near specificity of TRAIL, reports of multiple resistance 
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pathways to TRAIL-induced apoptosis significantly lowered the enthusiasm of 
considering TRAIL as an efficient anti-tumor therapeutic modality (Joy et al, 2003).  
 
Blockade of the apoptotic signal generated by ligand binding to the TRAIL receptor 
can occur at several steps along the pathway. The most prominent and well-studied 
ones being lowered ratio of surface death to decoy receptors,  increased ratio of  c-
FLIP to caspase 8, upregulation of the anti-apoptotic proteins of the Bcl-2 family,and 
IAP family proteins as represented in Figure 2. The other context and cell type 
specific prosurvival pathways implicated in TRAIL resistance include the PI3-K- 
Akt, NF-κB and MAPK pathways. 
 
3.1.1 Ratio of surface death to decoy TRAIL receptors  
 
Tilting the balance towards increased expression of surface decoy receptors 
eventually leads to a decreased chance of TRAIL binding to its death receptors. As 
the decoy receptors compete with the death receptors for ligand binding, the 
efficiency of TRAIL death signaling gets severely compromised. The mechanisms by 
which this ratio is achieved includes decreased transport of death receptors to the 
surface of the cell (Jin et al, 2004), activation of mechanisms favouring death 
receptor endocytosis (Zhang & Zhang, 2008) or mutations that lead to epigenetic 
silencing of functional death receptors (Elias et al, 2009; Horak et al, 2005). A 
detailed quantitative analysis shows the correlation between surface receptor 
expression of decoy receptors and resistance to TRAIL (Buneker et al, 2009) and this 
highlights the importance of inhibiting decoy recptors for efficient TRAIL signaling. 
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3.1.2   Ratio of c-FLIP to caspase 8 
 
The function of c-FLIP is self-explanatory as FLIP stands for FLICE (FADD-like 
interleukin-1beta-converting enzyme – caspase 8) inhibitory protein. Increased 
expression of c-FLIPS/L which is a pseudo form of caspase 8, allows binding to the 
DISC via its DD (Irmler et al, 1997).  However, c-FLIP has no functional similarity 
in terms of protease activity to caspase 8 and thus cannot activate the caspase 
cascade and initiate apoptosis. Inhibition of the DISC can also occur due to 
mutations that lead to functional inactivation of caspase 8. A number of parallel 
studies have shown that caspase 8 can be inactivated, either by deletion of the 
caspase 8 gene or due to epigenetic silencing such as methylation (Casciano et al, 
2004; Teitz et al, 2000). These mutations render tumors highly malignant, especially 
some neuroblastomas and make them completely resistant to apoptosis.  
 
3.1.3   Upregulation of the anti-apoptotic Bcl-2 and IAP family proteins  
 
When the mitochondria is engaged to enhance cell death initiated by ligand-binding 
to surface receptors or when the mitochondria is directly targeted by drug triggers, 
resistance to TRAIL-induced apoptosis can arise due to increased ratio of 
antiapoptotic Bcl2 family members to pro-apoptotic ones. As elaborated earlier, 
proteins such as Bcl2, Mcl-1 and Bcl-w can bind to Bax or Bak and dampen their 
pro-apoptotic function.  The significant part played by Bcl-2 in inhibiting apoptotic 
signal transduction through the mitochondria has been studied on a panel of glioma 
cells (Hetschko et al, 2008). In an interesting study by (Fulda et al, 2002),   the role 
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of Bcl-2 in regulating caspase 8 expression has been shown, suggesting that this 
caspase is regulated both upstream and downstream of the mitochondria. Resistance 
arises as the increase in antiapoptotic Bcl-2 stabilizes the mitochondria and maintains 
mitochondrial integrity in tumor cells when a compromised mitochondria that can 
release apoptogenic proteins is important for apoptosis.  
 
Along with preventing release of cyt c, IAP inhibitors such as Smac/DIABLO are 
prevented from being released, thus allowing IAP‟s to directly inhibit initiator 
caspases such as caspase 9 and effector caspases such as caspase 3/7. The link 
between IAP‟s and TRAIL resistance is elucidated in complementary studies 
wherein the presence of IAP‟s inhibited TRAIL signaling (Ndozangue-Touriguine et 
al, 2008), while it‟s silencing increases susceptibility of tumor cells to TRAIL-
induced apoptosis (Vogler et al, 2008). 
 
3.1.4   PI3-K- Akt, NFκB and MAPK pathways 
 
Protein Kinase B or Akt is a serine/threonine kinase that is activated by the growth 
factor signalled PI3-K pathway. Constitutive phosphorylation of Akt has been shown 
to be able to mediate TRAIL resistance mainly in acute lymphoblastic leukaemia 
(ALL) (Dida et al, 2008), acute myeloid leukaemia (AML) (Martelli et al, 2006), 
breast cancer cell (Xu et al) and in prostate cancer cells (Chen et al, 2001).        
                                     
Likewise, Rel/NF-κB protein is a dimeric transcription factor involved in regulating 
both cell proliferation as well as apoptosis. Activation of NF-κB is regulated by IκB 
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which prevents nuclear localization of NF-κB by masking its nuclear localization 
signal (NLS). Activation of IκB kinase (IκK) phosphorylates IκB, causing it to be 
proteasomally degraded, which allows release of sequestered NF-κB and its 
subsequent nuclear translocation. In the nucleus, NF-κB binds to consensus 
sequences on the promoter regions of its pro- and anti-apoptotic target genes. Thus, 
depending on the target protein activated, NF-κB can either sensitize or inhibit 
TRAIL signaling (Ammann et al, 2009; Dalen & Neuzil, 2003; Thayaparasingham et 
al, 2009). However, a majority of studies implicate activation of NF-κB with 
resistance to cell death.  Infact, a correlation between levels of NF-κB activation and 
TRAIL resistance has been shown by (Ehrhardt et al, 2003; Yang & Thiele, 2003). 
Furthermore, some representative observations that make us realize the fact that most 
signaling cascades are not watertight compartments but are interacting with each 
other to a large extent are of interest. Activation of the PI3-K-Akt pathway enhances 
expression of  c-FLIP directly in gastric cancer cells (Nam et al, 2003) or via 
activation of the transcription factor NFκB  in HL-60 leukemia (Bortul et al, 2003), 
leading to TRAIL resistance.  
 
Like most proteins involved in signaling pathways, MAPK (Mitogen-activated 
Protein kinases) family of proteins consisting of ERK (extracellular-signal regulated 
kinase), JNK (c-Jun N-terminal kinase) and p38 have been implicated both in cell 
survival and cell death. Depending on the upstream signal and on the cellular mileu, 
the downstream targets activated vary and generate different end-points in cellular 










Figure 2:  Factors affecting sensitivity of cells to TRAIL 
Various mechanisms by which cancer cells exhibit   resistance to 
TRAIL and hence evade TRAIL-induced apoptosis (G. Mellier et 








3.2  STRATEGIES TO OVERCOME OR ENHANCE SENSITIVITY OF CELLS   TO  
TRAIL  -  SMALL MOLECULE COMPOUNDS AS SENSITIZERS 
 
Having introduced the mechanisms of TRAIL resistance in the preceding section, it 
is now evident that tumor cells have developed myriad ways to become insensitive to 
this drug.  It is understood that tumor cells can vary both in terms of mechanism and 
intensity of resistance to TRAIL - ranging from moderate to complete. This has 
certainly been a cause of worry that has made us ponder over the possible ways by 
which TRAIL sensitivity can be restored or heightened in tumor cells. One 
straightforward means of tackling this issue is to pretreat tumor cells with drugs that 
can tweak the intracellular status of the cell to overcome the blockade and facilitate 
TRAIL-mediated apoptosis.  
 
Various approaches that include inhibiting pro-survival pathways, activating pro-
death pathways and altering the intracellular redox/ ionic homeostasis in the cells 
have been studied. Drugs that target these mechanisms and particularly those that 
modulate ROS levels in tumor cells to enhance sensitivity to TRAIL are of particular 
interest. This study is on one such drug that has made an attempt to elucidate the 
signaling hierarchy activated by LY303511 that leads to enhanced TRAIL 
sensitivity. Other drugs such as the flavanoid Silibinin; the lactones Andrographolide 
and Withaferin A have also been shown to upregulate death receptors in response to 
different upstream signals (Lee et al, 2009; Son et al, 2007; Zhou et al, 2008).  In 
addition, an interesting unexpected link between synthetic PPAR-γ ligands such as 
Ciglitazone, Troglitazone Rosiglitazone, and surface increase in TRAIL death 
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receptors was discovered by (Kim et al, 2008; Zou et al, 2007). Interestingly, many 
of the drugs that enhance TRAIL sensitivity by increasing receptor levels also inhibit 
survival advantage by lowering c-FLIP expression. These and other related studies 
reinforce the understanding of the effect of c-FLIP on inhibiting TRAIL signaling 
(Siegmund et al, 2002).  In addition to inhibiting c-FLIP, suppressing activation of 
other proteins that inhibit apoptotic signaling via the mitochondria include ABT 737, 
Kaempferol and XIAP inhibitor 1 and 2.  ABT-737 is a small-molecule BH3 mimetic 
that specifically antagonizes Bcl-2/Bcl-xL and also enhances expression of TRAIL 
receptors (Huang & Sinicrope, 2008; Song et al, 2008). Inhibition of XIAP using 
small molecule XIAP inhibitors 1 and 2 has been shown to efficiently surpass the 
resistance exerted by Bcl-2 to TRAIL-induced apoptosis (Fakler et al, 2009). 
Another survival pathway that is most often targeted is the PI3K-Akt pathway and is 
one of the mechansism employed by drugs such as LY29. A study by (Siegelin et al, 
2008) shows the enhanced combined effect of Kaemferol on suppressing Akt activity 
and thereby promoting proteosomal degradation of survivin for TRAIL senistization. 
Similarly, sensitizers that have been shown to enhance TRAIL sensitivity also 
include drugs that target the proteasome such as MG132, Bortezomib and Histone 
deacetylase (HDAC) inhibitors such as Trichostatin A (Nencioni et al, 2005; Singh et 
al, 2005). Resveratrol, Quercetin and LY303511 are drugs that have been shown to 
allow redistribution of these death receptors in the lipid rafts. This helps to bring the 
receptors closer to facilitate pre-oligomerisation. Interesting studies by a few groups 
have tried to understand the mechanism by which these preformed receptor clusters 
transduce apoptotic signals more efficiently upon ligand binding (Delmas et al, 2004; 
Poh et al, 2007; Psahoulia et al, 2007).  
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4.   ROLE OF ROS IN REGULATING SIGNALING PATHWAYS 
 
4.1   MITOCHONDRIA AS A SOURCE OF ROS 
 
ROS are chemically reactive oxygen derivatives produced as natural byproducts of 
cellular metabolism by mitochondrial respiration. The electron transport chain (ETC) 
shuttles electrons through the ETC complexes, thereby creating a proton gradient that 
leads to ATP production. Molecular oxygen is the final electron acceptor which 
undergoes reduction to water in the presence of 4 electrons and 4 protons. However, 
along its journey through the ETC complexes, electrons can leak out and react with 
molecular oxygen, giving rise to reactive oxygen species (ROS) (Jezek & Hlavata, 
2005; Liu et al, 2002). One or two electron reduction of molecular oxygen yields 
superoxide anion and peroxide ions respectively. The superoxide anion is an 
extremely short-lived (estimated half-life of 400-10
-6
 ns), biologically reactive free 
radical and is usually seen as an initiator of the ROS cascade. In the presence of the 
enzyme manganese or copper-zinc superoxide dismutase (Mn or Cu/Zn SOD), 
superoxide anion gets dismutated in to non-radical ROS such as H2O2 molecules. 
Furthermore, superoxide anion and H2O2 can be catalysed by iron to yield the potent 
hydroxyl radical by a process known as Haber-Weiss reaction. Additionally, 
superoxide can also react with the free radical nitric oxide to produce peroxynitrite.  
 
4.2   OTHER SOURCES OF INTRACELLULAR ROS 
Apart from the mitochondria, the other physiological sources of intracellular ROS 
production include oxidases such as the plasma membrane bound enzyme complex, 
NADPH oxidase which respond to external stimuli. The NADPH oxidase complex 
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consists of different isoforms of transmembrane proteins of the NOX family, the 







known as stabilizer, organizer and activator subunits respectively, the NADPH-
oxidase complex is functional.  This complex was first studied in macrophages and 
neutrophils which produce ROS as a respiratory burst aiding phagocytosis (Mizrahi 
et al, 2006). NOX2 is activated upon binding to p22
phox 
and together form the flavin 
binding cytochromeb558, which has been recognized as an important electron 
shuttler from the cytosol through the complex. Contrary to the ROS produced by the 
mitochondria as a byproduct of cellular respiration, NADPH oxidase system is 
dedicated to superoxide production.  
 
Similarly, Xanthine oxidase is a large complex of molybdenum atoms, flavin 
molecules and clusters of iron-sulphur. It is mainly localised in the liver were it is 
present in the form of xanthine dehydrogenase. The reaction of the molybdenum 
moiety with uric acid occurs simultaneously with electron reduction of the terminal 
oxygen (oxo), generation of superoxide anion in this process has been shown to 
induce oxidative stress under ischemic conditions (Griguer et al, 2006). The other 
oxidases are cellular enzyme systems such as the peroxisomal oxidases of micro 
(peroxisomes), ER oxidases of endoplamic reticulum and they all function by 
shuttling electrons through their enzyme complex and generating superoxide anion 
via reduction of molecular oxygen. The lesser known ROS sources in the cytosol 
include the arachadonic acid cascade that generates ROS by lipid metabolism. Some 
cytochrome P-450 isozymes, autooxidation reactions of ascorbic acid and low 
molecular weight thiols can also act as minor sources of ROS generation. 
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4.3      RATIONALE FOR SCAVENGING ROS USING ANTIOXIDANTS AS AN 
APPROACH TO TUMOR THERAPY 
 
There are many theories and approaches to understand how cancer develops and 
what role reactive oxygen products contribute to the same. One such theory is that 
during the process of transformation, highly respiring cancer cells produce large 
amounts of ROS via increased oxidative phosphorylation. This endogenous increase 
in ROS acts as a strong oxidant that exerts damaging effects on biological 
macromolecules such as nucleic acids and proteins leading to mutations and 
initiating tumorigenesis. Development of cancer came to be known as a process of 
selection for cells that can sustain these ROS levels and the oxidative stress. Initial 
studies on ROS led to the understanding that the presence of low oxidative stress in 
tumor cells can make cancer cells adapt to this cellular state of increased ROS. The 
cells that survive the selection pressure have an advantage to drive tumor cell 
proliferation and maintenance as summarized by (Clerkin et al, 2008) and this also 
provides it with the ability to be insensitive to drug triggers.  Exploiting this altered 
redox (reduction-oxidation) status wherein tumor cells have intrinsically higher 
levels of ROS with insufficient antioxidant defences, marked the use of 
supplementing tumor cells with exogenous antioxidants to scavenge ROS as tumor 
therapy.  Non-enzymatic dietary antioxidants such as Quercetin, All-trans retinoic 
acid (RA) or 13-Cis-retinoic acid (cRA), Vitamin E succinate (VES) or alpha 
tocopherol succinate and selenium have been linked to tumor reduction following 
treatment (Lamson & Brignall, 1999). Quercetin being a phenolic compound can 
react with free radical species to form phenoxy radicals which are slightly less 
reactive and its role in antioxidant defense leading to reduced proliferation of human 
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hepatoma cells is shown by (Alia et al, 2006). The promising results obtained with 
RA and cRA in Acute promyelocytic leukemia (APL), human small cell lung cancer 
lines and prostate cancer made them antioxidants of choice (Culine et al, 1999; 
Doyle et al, 1989; Nikolaou et al, 1996; Warrell et al, 1991). Interest in VES in 
tumor therapy was following the observation that it inhibits growth and apoptosis in 
human B-cell lymphoma and estrogen receptor-negative breast cancer cell lines 
(Turley et al, 1997; Turley et al, 1995).  
 
4.4    TO DECREASE OR NOT TO DECREASE ROS IN TUMOR THERAPY? 
One interesting turn came about in the early 90‟s when it was observed that 
chemotherapeutic agents such as Doxorubicin, Bleomycin and Cisplatin also 
generate ROS. While some believed that this ROS was part of its mechanism for 
killing tumor cells, most studies described the systematic toxic side-effects on 
normal cells causing lipid peroxidation mediated cardiotoxicity and nephrotoxicity 
(Alberts & Noel, 1995; Prasad et al, 1999; Weijl et al, 1997). And thus, antioxidants 
found use in another aspect of tumor therapy, as an adjuvant that could reduce 
deleterious effects on normal cells by scavenging ROS (Kalemkerian et al, 1998; 
Myers et al, 1983) and acting synergistically to enhance the efficacy of 
chemotherapy, radiation therapy on tumor cells (Kurbacher et al, 1996; Ohkawa et al, 
1988). However, the antagonistic effects of this combination therapy has surfaced in 
studies by (Labriola & Livingston, 1999; Raich et al, 2001), again suggesting that the 
ROS produced by these drugs might play a role in signaling for cell death.  
 
Understanding that tumor cells exhibit intrinsically higher levels of ROS that aids in  
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inducing DNA damage and genomic instability, this approach in tumor therapy is 
based on the premise that targeting the state of oxidative siege of cancer cells by 
overwhelming them with drug triggers that produce ROS beyond their survival 
threshold could be the way to go (Haddad, 2004). In addition, tumor cells might be 
coping with this intrinsic oxidative stress with whatever resources of antioxidant 
systems they have and thus, using antioxidant inhibitors was the next option in tumor 
therapy (Kong & Lillehei, 1998). In addition to chemotherapeutic drugs, effect of 
drugs such as arsenic trioxide on acute promyelocytic leukemia cells is noteworthy. 
Although oxidative stress induced apoptosis has been shown, an overwhelming 
increase in ROS is usually associated with necrotic cell death.  
  
4.5   A NEW APPROACH - UNDERSTANDING DIFFERENCES IN THE ROS SPECIES 
PRODUCED 
Most early studies looked at ROS from a general point of view and most conclusions 
on ROS regulation of cellular processes were made assuming that all species of ROS 
had the same function in tumor cells. However, considering the different types of 
ROS that can be produced and the biochemical differences between them, it is most 
probable that each species of ROS might have higher affinity for a certain class of 
biological molecules and have widely different downstream effects in a tumor cell. 
Consequently, it was seen that the ROS produced by external stimuli such as heat, 
stress, DNA damage, and certain drugs either through the mitochondria or through 
the oxidase systems can tranduce signals to trigger either tumor cell proliferation or 




Early efforts by   (Burdon, 1995),  to understand superoxide and hydrogen peroxide  
as signaling molecules looked at the growth response of hamster fibroblasts (BHK-
21), Balb/3T3 cells and human histiocytic leukemia cells (U937) in response to a 
slight increase (10 nm – 1 µM) in superoxide. An obvious increase in growth was 
concomitant with increased expression of c-jun and c-fos genes and this hinted a 
prosurvival role for superoxide anion. Although a prosurvival role was also indicated 
for low levels of H2O2, as was seen in BHK-21 cells and mouse osteoblastic cells 
(MC3T3), it was clarified that these responses were highly dependent on the cell type 
and the amount of ROS produced. Evidence of apoptotic cell death upon exposure of 
BHK-21 cells to intermediate levels (10 -100 µM) of H2O2 (Burdon et al, 1996) and 
the differential response of H2O2 in cells by inhibiting DNA synthesis in some tumor 
cells (Shibanuma et al, 1991) established a proapoptotic role for H2O2. In addition, 
reports on the role of proxidant setting in tumor promotion were suggested in early 
studies by (Cerutti, 1985; Oberley & Buettner, 1979). 
 
A better understanding of ROS from this perspective was made possible by studies 
by (Clement et al, 1998; Clement & Stamenkovic, 1996; Pervaiz et al, 1999),                                             
showing that Fas-mediated apoptosis was decreased upon inhibition of the SOD 
enzyme. This implied that an increase in superoxide anion as a result of inhibiting an 
enzyme that scavenges it could lead to survival of human hepatoma cells. This 
interesting data was followed up by supporting studies showing that a decrease in 
superoxide via inhibition of the NADPH oxidase enzyme complex could enhance 
apoptosis in tumor cells. This hypothesis stood true across various tumor cell lines 
and drug triggers corroborating that a species-specific increase in superoxide creates 
a prooxidant state accompanied by an increase in intracellular pH and this 
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preferentially signals for cell proliferation. Indeed, several reports on vascular 
smooth muscle cells (VSMC) and on endothelial cells wherein decrease in 
superoxide anion production by overexpression of Cu/Zn SOD leads to reduced cell 
growth implicate superoxide anion as a signal for cell proliferation (Lee et al, 1998; 
Li et al, 1997b; Zanetti et al, 2001). Supporting this observation, are studies showing 
that lung cells transformed with constitutively active Ras mutant (H-ras-V12) 
produced increased intracellular superoxide via the NADPH oxidase complex. This 
increase in superoxide led to resistance to TNF α treatment and conversely, 
scavenging of superoxide by SOD overexpression decreased resistance to TNF α 
(Liu et al, 2001). In contrast, overexpression of Cu/Zn SOD led to a lowered 
cytosolic pH and correspondingly enhanced sensitivity to triggers. Recalling that 
SOD is an enzyme that catalyzes conversion of superoxide to hydrogen peroxide, the 
results pointed to the possibility that the presence of H2O2 creates a reduced 
intracellular setting and acts as a cell death signal for tumor cells. As is the case for 
most biological molecules, the important point to note is that depending on the 
amount of H2O2 produced, it can induce different outcomes where a large increase is 
associated with the necrotic form of cell death and a moderate increase is linked to 
apoptotic signaling. 
 
4.6  INCREASING SPECIES-SPECIFIC ROS AND PHARMACOLOGICAL 
TAILORING OF CELLS  AS A TUMOR THERAPY 
 
Studying biological functions such as ion or redox homeostatsis has never been easy. 
It is important to understand that tumor cells have their own “redox signaling 
signature” wherein its basal levels of different species of ROS, antioxidant defense 
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systems and cellular signaling network (oncogenes, transcription factors that can also 
contribute to ROS production) most certainly determine their proliferation rate, drug 
resistance and signaling cascades that can be initiated (Wang & Yi, 2008). However, 
the knowledge that modulating a tumor cell via induction of slight to intermediate 
levels of H2O2 can tilt the balance favouring apoptosis is corroborated by a number 
of studies. Preliminary evidence came from studies by (Ahmad et al, 2004), showing 
that drug-induced apoptosis of tumor cells is associated with H2O2 mediated 
cytosolic acidification which allows change in conformation and translocation of Bax 
to the mitochondria and subsequent apoptosis. This indication that drug mediated 
changes in cytosolic pH can be used to modulate tumor cell response and signaling 
was corroborated by a number of studies by (Lopez-Lazaro, 2007; Mao et al, 2006; 
Singh et al, 2007).  
 
In addition to inducing apoptosis, an even more interesting observation has been that 
preconditioning tumor cells with H2O2 can make it an efficient sensitizer to apoptosis 
induction by other drugs. This possibility was tested in studies on LY303511 to 
obtain encouraging data (Poh & Pervaiz, 2005; Shenoy et al, 2009). The studies 
show that this priming enhances the efficacy of chemotherapeutic drugs and 
proapoptotic receptor ligands such as TNF and TRAIL. Also, corroborating this 
school of thought is a study on Wogonin wherein the ability of this drug to produce 
H2O2 suppresses NF-κB and allows enhanced sensitivity to TRAIL-induced 





5.  ROS-MEDIATED SIGNALING CHANNELS  
 
5.1   ROLE OF H2O2 IN THE EXTRINSIC PATHWAY 
 
Regulation of the components of the extrinsic pathway by ROS includes control of 
cell surface receptors, proteins involved in DISC formation and caspase 8 and has 
been of significant interest. The regulation of redox-activated transcription factors 
such as AP-1, NF-κb and p53 all of which have been shown to upregulate receptors 
of the extrinsic cell death pathway is an indirect link to show that these receptors 
might be under oxidative control. Redox-mediated modification of cysteine residues 
on DNA-binding sites of target protein promoter regions as seen for c-fos, c-jun and 
their dimerization product, AP-1 is one method by which cells regulate them.                                    
Also, oxidant-stimulation allows release of NF-κB from its inhibitory protein IκB, 
thereby promoting its nuclear translocation.  
 
The redox regulation of other transcription factors such as p53 and c-EBP 
homologous protein (CHOP) has also been extensively reported.  All caspases are 
cysteine proteases and the presence of these cysteine residues in their active site 
makes it a target of oxidative modifications, mainly via Thioredoxin (Trx1). Indeed, 
studies have shown that caspase activity is enhanced under reduced conditions by 
mild increase in H2O2 (Hampton & Orrenius, 1997; Izeradjene et al, 2005; Ueda et al, 
1998). The possible involvement of H2O2 in c-FLIP regulation is suggested in studies 
by (Nitobe et al, 2003), showing that this regulation decides susceptibility of cardiac 





5.2    ROLE OF H2O2 IN MODULATING KINASES AND PHOSPHATASES  
 
The role of spontaneously or enzymatically produced H2O2 in regulating signaling 
cascades came from studies showing that abrogating intracellular levels of H2O2 
using its scavenger catalase led to decrease in growth factor induced receptor 
tyrosine phosphorylation and MAPK activation in rat vascular smooth muscle cells 
(Bae et al, 1997; Sundaresan et al, 1995). Efforts to understand the possible 
mechanism by which H2O2 may be regulating proteins led to a logical trail of 
thought. Since it had been observed that H2O2 is a mild oxidant, it was considered a 
possibility that this chemical characteristic of H2O2 would allow it to post-
translationally modify cysteine residues on proteins via oxidation to form cysteine 
sulfenic acid or disulphides (Pirie, 1931). One class of proteins that are are 
susceptible to this oxidative modification include phosphatases such as Protein 
Tyrosine Phosphatases (PTPs). The presence of the cysteine residue in the active site 
of these phosphatases makes it possible to be readily and reversibly oxidized leading 
to its inactivation. Similarly, another family of phosphatases known as the serine 
threonine phosphatases that include PP1, PP5, PP2A, PP2B and PP2C can be redox 
regulated. Inactivation of PP2B by oxidative modification of a pair of conserved 
cysteine residues by H2O2 in a dose-dependent manner has been reported. Near 
similar results have been obtained for PP1 and PP2A. Studies on neuronal apoptosis 
have highlighted the role of H2O2 to control phosphatases, mainly MAP kinase 
phosphate-1 (MKP-1), PP2A and PP5 (Chen et al, 2009; Franklin & Kraft, 1997). It 
is known that phosphorylation of a protein is a balance between the upstream kinase 
phosphorylating it and a phosphatase that negatively regulates this process. Thus, 
oxidation of phosphatases and its subsequent inactivation allows activation of 
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proteins that it would otherwise inhibit from getting phosphorylated. Therefore, 
activation of many of the serine threonine kinases such as MAPK; Protein tyrosine 
kinases (PTK) such as Janus kinase (JAK) by H2O2 could be attributed to the 
inactivation of their regulating phosphatases. Apart from regulating the MAPK 
cascade activation by phosphatase inhibition, some interesting reports indicate a 
novel method of directly regulating activation of MAPKs. Although the conventional 
pathway of Ras activation involves ligand (growth factor) binding, recent studies 
indicate the presence of an oxidation–sensitive cysteine residue on Ras aids guanine-
nucleotide exchange on it, thereby activating it and this represents an additional 
means by which H2O2 can directly regulate the MAPK pathway by modulating 
upstream proteins (Mitchell et al, 2012). In addition, the MAP3K ASK1 forms an 
inactive complex with the reduced form of the redox-sensitive regulatory protein 
Trx1 that prevents ASK1 feombeing functional. The oxidation of two critical 
cysteine residues in the active site of Trx1 allows ASK1 to dissociate itself from 
Trx1 and get activated. This initiates the activation of the JNK MAPK cascade and 
the ensuing downstream target proteins (Saitoh et al, 1998). 
5.3   THE MAPK PATHWAY 
 
The mitogen activated protein kinase (MAPK) pathway is indeed one of the best 
studied redox-regulated pathways. Proteins belonging to this family are proline 
directed serine threonine kinases that act as efficient signaling proteins that transduce 
extracellular signals via cell surface receptors to the proteins in the cytosol. They 
form a three-tier ssequential signaling cascade wherein a MAPK kinase kinases or 
MAP3K (signal sensor) activates MAPK kinases or MAP2K (signal relayer) that 
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then activates MAPK (signal executor) which activates a host of target proteins 
(Wada & Penninger, 2004). MAPKs are activated by dual phosphorylation on their 
threonine and tyrosine residues in the conserved tripeptide motif and subsequently, 
phosphorylate their substrates on the hydroxyl side chains of serine and threonine 
residues (Ferrell & Bhatt, 1997; Widmann et al, 1999). Interestingly, the successive 
phosphorylation on the phosphoacceptor threonine and tyrosine residues is a planned 
two-step process. The first phosphorylattion on tyrosine residues helps the protein to 
get accumulated without actually getting activated and upon sufficient increase; it 
gets phosphorylated on the threonine residue allowing complete activation. Thus, 
they also act as signal amplifiers as each subsequent activation in the cascade leads 
to more abundant downstream protein production. Although MAPKs need to be 
phosphorylayed on both their residues before getting activated, action of 
phosphatases and removal of any one of the phosphate groups is sufficient for its 
inactivation (Tarrega et al, 2010). Along with playing a role in physiological 
functioning such as cell differentiation and embryogenesis, its important role in 
regulating tumor cell proliferation and death has been shown. The MAPK siganling 
proteins constitute the extracellular signal-regulated kinases (ERK), c-Jun-N-
terminal kinases (JNK) and p38. These three signaling channels are closely linked as 
they respond to similar stimuli and have overlapping substrate specificites. 
5.3.1    The ERK subfamily 
 
 
5.3.1.1   Activators and substrates of ERK 
 
The p42/44 ERK subfamily of MAPK constitutes two isoforms (ERK1 and 2) which 
are significantly identical to each other, especially in the core regions but are not 
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functionally redundant. Most early studies on ERK were done on fibroblasts where it 
was observed that ERK is activated in response to growth factors that act as ligands 
for G protein-coupled receptors (GPCR) and growth factor receptors (Citri & 
Yarden, 2006). The ERK cascade begins with the ligation of receptor tyrosine 
kinases (RTK), allowing its autophosphorylation in the cytosolic side on tyrosine 
residues. This signals for recruitment of adapter proteins such as growth factor 
receptor bound protein 2 (Grb2) and guanaine nucleotide exchange factor (GEF).  
SOS (son of sevenless) is a GEF which facilitates guanine nucleotide exchange on 
Ras (GDP with GTP) which allows conformational change and activation of Ras. 
Activated Ras then binds Raf isoforms (Raf-1, A-Raf, B-Raf; MAP3K) with strong 
affinity at the Ras binding domain (RBD) and cysteine-rich domain (CRD) allowing 
Raf to get activated at the membrane. The downstream substrate of active Raf is 
MEK1/2 (MAP/ERK kinase 1/2; MAP2K) which gets phosphorylated by activation 
at two critical serine residues. MEK is a dual specificity kinase that phosphorylates 
its substrate ERK1/2 on its threonine and tyrosine residues, thereby activating it 
(Chang et al, 2003). ERK is a serine threonine kinase that phosphorylates its vast 
number of downstream targets on serine and threonine residues that is present after 
the proline residue. Of the many cytosolic targets of activated ERK, one of the most 
important one is the ribosomal protein S6 kinases (RSKs) which can translocate to 
the nucleus to phosphorylate c-fos, serum response factor (SRF) and cyclic AMP 
response element-binding protein (CREB) (Richards et al, 2001). In the nucleus, 
ERK can directly phosphorylate and activate the AP-1 component ATF1. Most 
importantly, it regulates activation of the ternary complex factors (TCFs), including 











                       Figure 3: The MAPK family signaling pathway 
            Modified from PJ Roberts and CJ Der; Oncogene (2007) 26, 3291–3310 
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Since two upstream activators of the ERK pathway, Ras and Raf are known 
protooncogenes and since this pathway is usually activated in response to growth 
factors, it is more often looked at as an antiapoptotic signaling cascade (Daouti et al, 
2009; Watanabe et al). However, it should be considered that the output of ERK 
signaling is dependent on the cell type, the kind of stimuli and the substrates it 
activates. Understanding this has led to a number of recent studies that have focussed 
on its proapoptotic role (Zhuang & Schnellmann, 2006). The proapoptotic role of 
ERK was first seen by (Bhat & Zhang, 1999), where inhibition of ERK was seen to 
rescue oligodendroytes from H2O2 induced cell death. Following this, apoptotic cell 
death by ERK activation has been implicated in various cellular systems including 
cervical carcinoma cells, osteoblasts, renal epithelial cells, hepatoma cells and bone 
marrow stromal cells in response to various triggers like cisplatin, H2O2 and 
Resveratrol (She et al, 2001; Wang et al, 2000). The role of ERK in regulating 
components of the extrinsic pathway has been hinted by studies showing 
upregulation of death receptors of Fas, TNFα and TRAIL signaling pathway and 
regulation of caspase 8 activity (Goillot et al, 1997).  
 
5.3.1.2   Specific interactions of ERK 
ERK has a wide array of activators, negative regulators and substrate or target 
proteins with which it interacts. Its activation by kinases is modulated by the 
opposing action of phosphatases such as dual specificity threonine/tyrosine MAP 
kinase phosphatases (MKPs) or dual specificity phosphatases (DUSPs), protein 
serine/threonine phosphatases (PSPs), and protein tyrosine phosphatases 
(PTPs)(Junttila et al, 2008). ERK interacts with its target proteins through docking 
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domains such as the D-domain (also known as the DEJL motif) and the DEF-domain 
(also known as the FxFP motif) (Fantz et al, 2001; Sheridan et al, 2008). In addition, 
the localization of ERK determines which substrates it can access and this is another 
way by which ERK regulates biological outcome (Harding et al, 2005). Upon 
activation of ERK by upstream signals, phosphorylation dependent conformational 
change and homodimerization may expose its nuclear import sequence, allowing 
translocation to the nucleus.  Thus, the activation-dependent intracellular 
relocalization of ERK is an interesting aspect of study and some recent studies 
indicate its importance in determining substrate availability and ERK targeting to a 
large extent. Upstream scaffold proteins such as Kinase suppressor of Ras (KSR) and 
Connector enhancer of KSR (CNK1) are proteins that help determine the specificity, 
amplitude and duration of ERK activation (Claperon & Therrien, 2007; Roy et al, 
2002). One such novel scaffold protein that forms a part of this study is the 
phosphoprotein enriched in astrocytes (PEA-15). PEA-15 regulates ERK by 
sequestering it in the cytosol and thereby by preventing its nuclear translocation 
(Ramos, 2008). PEA-15 binds via a region at its own DED (Death effector domain) 
with the MAP kinase insert region of ERK located adjacent to the phosphorylation 
loop (Chou et al, 2003). Interestingly, this interaction can occur independent of 
ERK‟s activation state and is unique as it does not fall in to any one the previously 
known categories of ERK interactors such as phosphatases, upstream scaffolding 
proteins or docking proteins in terms of sequence similarity or functional outcome. 
Thus, even though ERK gets activated in the presence of upstream activating signals, 
the presence of PEA-15 can prevent it from exerting the biological end-point of 
activation in some systems. 
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5.3.1.3    The ERK - PEA-15 nexus and the role of PKC in regulating MAPKs 
Protein Kinase C (PKC) is a kinase belonging to the serine/threonine kinase family 
that contains 11 different isoforms. The isoforms perform a large number of varied 
functions and require different co-activators. The classical isoenzymes, α, βI, βII, and 
γ, require calcium and diacylglycerol (DAG) for activation; the novel isoenzymes, δ, 
ε, ε and ζ require only DAG while the atypical isoenzymes, δ, μ, and I/λ, do not 
require calcium or DAG but instead require ceramide and PIP3 as co-factors. PKC‟s 
contain regulatory and catalytic subunits that module its activity. The presence of a 
pseudo-substrate region keeps it in an inactive conformation while the cysteine-rich 
domains (CRDs) in the regulatory subunit allow binding of PKC to activator 
compounds, such as diacylglycerol (DAG) and a DAG miminc, phorobol 12-
myristate 13-acetate (PMA). Upon activation, most PKC isoforms are recruited to the 
membrane after phosphatidyl-serine binding as this enhances their affinity for acidic 
membrane lipids. This makes observed redistribution of PKC to the membrane a 
measure of its activation. Signals that activate PKC include signals via GPCR, RTK 
and non-receptor PTKs, which can activate DAG and facilitate calcium mobilization 
via inositol triphosphate (IP3). Although activation of PKC is thought of as an 
anitiapoptotic signal, the presence of several different isoforms makes it necessary to 
look at each isoenzyme in a particular signaling system, instead of PKC from a 
general point of view. Recent studies have demonstrated the active role played by 
PKCs in cell death, wherein activation of conventional and novel PKCs in response 
to PMA induce efficient apoptosis in prostate carcinoma cells.  
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The possible crosstalk between the PKC and MAPK pathways was observed by early 
studies on various cellular systems (Brandlin et al, 2002; Ueda et al, 1996). Although 
it was known that the classical isoforms of PKC can activate the Raf-ERK pathway, 
recent studies show that novel and atypical PKCs can also activate this pathway. The 
importance of JNK in PKC-induced cell death is shown in studies where 
overexpression of the negative regulators of the JNK pathway abrogates PMA-
induced cell death in LnCAP prostate carcinoma cells (Meshki et al, 2010; Tanaka et 
al, 2003). Relevant to this study is the observation that ROS, in particular H2O2 can 
activate PKCα and PKCδ to induce cell death in COS-7 cells by oxidative 
modifications on cysteine residues in the regulatory domain (Konishi et al, 1997). 
However, the exact relationship between ROS, PKC and ERK is a challenge to 
decipher as perturbations in redox and ionic balance are extremely sensitive making 
precise and consistent measurements difficult.  
 
Though the evidence is not extensive, it is now being understood that signaling 
proteins like PEA-15 allow convergence of signals from PKC and ERK. The 
phosphoprotein PEA-15 is also known as the phosphoprotein enriched in diabetes 
(PED) 15 or MAT-1 (Araujo et al, 1993). This C terminal tail of this cytosolic 
protein contains two serine residues (Ser104 and Ser116) at which it can get 
phosphorylated and exists either as an unphosphorylated, monophosphorylated or 
bisphosphorylated protein. The N terminal contains a nuclear export sequence (NES) 
which predominantly helps to keep it in the cytosol. Similar to FLIP, PEA-15 also 
contains a DED and is able to bind to the DED of DISC.  This interaction has been 
shown to inhibit TNFα-induced apoptosis in astrocytes and TRAIL induced 
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apoptosis in tumor cells. Consequently, silencing PEA-15 sensitizes human non-
small cell lung cancer and B-cell chronic lymphocytic leukemia cells to TRAIL-
mediated apoptosis (Garofalo et al, 2007; Zanca et al, 2008). Phosphorylation at 
Ser104 is mediated by PKC while that at Ser116 is by calcium/calmodulin-dependent 
protein kinase (CaMKII) or Akt (Kubes et al, 1998; Trencia et al, 2003). The ability 
of PEA-15 to bind and control ERK localization is dependent on the phosphorylation 
status of PEA-15 at Ser104. Many studies on PEA-15 attribute phosphorylation of 
PEA-15 at Ser104 to stabilization of ERK antiapoptotic function. Since 
phosphorylation at Ser104 allows ERK to dissociate from it and translocate to the 
nucleus, a general perception associates the presence of ERK in the nucleus to 
survival. In addition, a prosurvival role for PEA-15 is indicated in studies showing 
that phosphorylation at Ser116 enhances the stability of PEA-15 and prevents its 
proteosomal degradation (Perfetti et al, 2007). When this phosphorylation occurs 
following Ser104 phosphorylation, the doubly phosphorylated PEA-15 can bind to 
the DISC and exert an antiapoptotic role (Condorelli et al, 1999).  
 
5.3.2   JNK in stress activated cell death  
 
Early studies showed that c-jun is a protein that gets phosphorylated in response to 
UV irradiation or Ras activation. The search for upstream activators responsible for 
phosphorylation of c-jun at Ser-63 and Ser-73 using affinity purification with c-Jun 
activation domain as a substrate, led to the discovery of c-Jun amino terminal 
kinase/stress-activated protein kinase cascade (JNK/SAPK) (Derijard et al, 1994; 
Hibi et al, 1993). The three main mammalian isoforms of JNK include JNK 1, 2, 3. 
While JNK 1 and 2 are expressed ubiquitously, JNK3 is expressed preferentially in  
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Figure 4: Structure of PEA-15 and regulatory action on ERK 
(A) Structure of PEA-15 indicating its N-terminal DED and C-terminal tail 
(Fiory, F. et al, Am J Physiol Endocrinol Metab 297: E592–E601, 2009) 
(B) Regulation of ERK by PEA-15 (concept taken from Renganathan H. et al, 
Biochem J. 2005 Sep 15;390(Pt 3):729-35) 
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the nervous system. The JNK signaling cascade is activated mainly by stress signals 
such as oxidative stress, heat shock and osmotic shock. Although the exact 
mechanism of how these signals activate the JNK cascade is unclear, there is an 
indication that these upstream triggers allow ligand-independent clustering and 
internalisation of cell-surface receptors such as TNF and EGF and thereby allow 
phosphorylation of JNK (Rosette & Karin, 1996).  
 
Depending on the upstream signal, different signaling kinases such as p21-activated 
kinase (PAK), small GTPase, Rac or cell division cycle protein 42 (cdc42) are 
activated. This allows activation of members of the MEKK family (MAP3K) that 
include the mixed lineage protein kinases (MLK), apoptosis signal-regulating kinase 
-1 (ASK-1), transforming growth factor -b activated kinase -1 (TAK1) or TPL2. This 
activates the MAP2KS, JNNK1/MKK4/SEK1 and JNKK2/MKK7 that act as 
activators of JNK/SAPK signaling (Fleming et al, 2000). As in the ERK pathway, 
presence of scaffolding proteins like JNK-interacting protein-1 (JIP-1) has shown to 
enhance efficieny of substrate activation (Dickens et al, 1997). The downstream 
substrates that have been identified for JNK include its direct substrate c-Jun that is a 
component of the AP-1 family of transcription factor and others such as ATF-2 
(activating transcription factor 2), Elk-1, p53, DPC4, Sap-1a and NFAT4 with the 
majority of them signaling for cell death (Bogoyevitch & Kobe, 2006).  
 
Thus, although it has been shown in some studies that JNK can induce cell 
proliferation (Bost et al, 1999), JNK is more often associated with cell death and is 
best studied with respect to its regulation of the Bcl-2 family proteins. Activation of 
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Bax, either by JNK-mediated direct phosphorylation JNK mediated phosphorylation 
of 14-3-3 which allows dissociation of Bax from inactive 14-3-3 complexes has been 
reported (Tsuruta et al, 2004). Antiapoptotic members of the Bcl-2 family such as 
Bcl-2, Bcl-XL and Mcl-1 have also been shown to be phosphorylated by JNK to 




MEFs failed to show the release of cyto c upon triggering with UV-irradiation 
(Tournier et al, 2000) and this is atrributed to its ability to regulate cleavage of Bid. 
Several studies have demonstrated the proapoptotic role of JNK in the TNFR1 
signaling pathway (Lin, 2003). In addition, physiological inhibition of MKP activity 
by ROS may cause prolonged JNK activation and some studies have indicated that 
MKP inhibition is sufficient for JNK activation following certain stimuli and this 
highlights the regulatory role played by phosphatases. 
 
5.3.3    p38 in stress-activated cell death  
 
Activation of the p38 subfamily of MAPK is a result of stress-inducing stimuli, 
similar to the ones that activate JNK and hence, p38 is also known as a stress-
activated protein kinase (SAPK) (Wagner & Nebreda, 2009). Similar to other 
MAPKs, p38 is a dual-specificity kinase which gets phosphorylated via a organised 
phosphorylation cascde. The MAP3K‟s that initiates signal transduction includes 
TAK1, ASK, DLK/MUK/ZPK, MEKK4 which activate MKK3 and MKK6. 
Evidence suggests the ability of Rho-like GTPases, Rac and cdc42 to activate PAK 
which may act as the most upstream signal initiator of p38 signaling cascade (Zhang 
et al, 1995). It has been observed in many studies that p38 shares upstream activator 
proteins with the JNK pathway and hence their role in many systems can be 
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overlapping. The role of p38 is mostly implicated in stress mediated cell death 
pathways, but its role in regulating cell cycle, apoptosis, inflammation, 
differentiation, tumor survival and tumor suppression has been studied (Phong et al, 
2010; Thornton & Rincon, 2009; Valladares et al, 2000). In addition, the active role 
played by p38 in inducing a sensescent phenotype in response to H2O2 and Ras 
activation is thought to be mediated by MKK 6 and MKK 3 (Wang et al, 2002).  
The first p38 substrate identified was the MAP kinase-activated protein kinase 2 
(MAPKAPK2 or MK2) (Stokoe et al, 1992). This substrate, along with MK3 (3pk), a 
protein closely related to it, have together been shown to activate substrates that 
include small heat shock protein 27 (Hsp 27) (Larsen et al, 1997), lymphocyte-
specific protein 1 (LSP1) (Huang et al, 1997), Na+/H+ exchanger isoform-1 (NHE-
1), cAMP response element-binding protein (CREB), transcription factor ATF1 and 








   PART 2 - OBJECTIVE OF THE STUDY 
 
LY294002 (2-(4-Morpholinyl)-8-phenyl-4H-1-benzopyran-4-one, Molecular weight  
- 307.34) is a morpholine derivative of Quercetin that strongly inhibits the tumor 
promoting PI3-K pathway. The synthesis of LY29 was a result of replacing the 
dihydroxyphenyl group at the 2-position of the chromone ring in Quercetin with 
morpholine. In comparision to its lead compound, LY294002 displays enhanced 
specificity towards the PI3-K survival pathway and it is this property that 
popularised its use as an anti-tumor drug. LY294002 has been extensively used as a 
single agent to kill tumor cells and has also been used in combination to sensitize 
tumor cells to drug-induced cell death.  
LY303511 (2-Piperazinyl-8-phenyl-4H-1-benzopyran-4-one, Molecular weight -   
306.4) is a product of a single-atom substitution in the morpholine ring of 
LY294002. This specific replacement of amine with oxygen at the 2-position in the 
morpholine ring sufficed to make it an inactive analogue of LY29 by stunting its 
ability to inhibit the PI3-K-Akt survival signal. Following its synthesis, LY30 has 
mainly been used as an inactive control for understanding the signaling by LY29.  
The initial observation from our lab that LY29 (at lower doses that does not 
significantly inhibit Akt activation) and LY30 (which does not inhibit Akt activation 
owing to its structure) could produce ROS, particularly hydrogen peroxide and could 
sensitize LnCAP prostate carcinoma cells to drug induced apoptosis was certainly 
interesting and warranted further understanding. These studies pointed to an alternate 
PI3-K independent mechansism by which these LY compounds could efficiently 
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sensitize tumor cells to drugs such as Vincristine and this formed the basis for the 
inception and objectives of this study: 
 To establish that hydrogen peroxide is indeed a crucial upstream molecule 
in LY30 signaling. 
 To elucidate the downstream signaling cascade by linking the hydrogen 




PART 3 – MATERIALS AND METHODS 
 
This curiosity to better our understanding of LY30 required various experimental 
setups and assays to be performed. The study mainly comprised of methods to 
determine the combinatorial effect of LY30 with TRAIL and specific protocols to 
decipher the signaling mechanism by which LY30 helps to enhance sensitivity of 
SHEP-1 cells to TRAIL- mediated apoptosis and  are as described below: 
 
Cell lines used in the study 
The neuroblastoma cell line SHEP1 is an epitheloid subclone of the cell line, SK-N-
SH and is classified as S-type or substrate adherent type of neuroblastoma cell line. It 
was grown in DMEM prepared by dissolving DMEM powder (Invitrogen Life 
Technologies, Carlsbad, CA, USA) in 1000ml of dH2O supplemented with 1.2 g 
HEPES and 1.74 g Sodium bicarbonate (NaHCO3), 10% Fetal Bovine Serum (FBS) 
and 1% Penicillin-Streptomycin (Pen-Strep). The neuroblastoma cell line SH-SY5Y 
was cultured in RPMI 1640 medium (Hyclone, Logan, Utah, USA) containing 10% 
FBS and 1% Pen-Strep. LnCAP prostate carcinoma cell line was grown in RPMI 
1640 medium (Hyclone, Logan, Utah, USA) containing 10% FBS, 1% Pen-Strep, 
1% Glutamine and 1% sodium pyruvate. The glioblastoma cell line T98G was grown 
in MEM (Minimal Essential medium - Invitrogen Life Technologies, Carlsbad, CA, 
USA) containing 10% FBS, 1% Pen-Strep and 1% Glutamine. T cell leukemia cell 
line Jurkat was grown in RPMI 1640 medium (Hyclone, Logan, Utah, USA) 
containing 10% FBS and 1% Pen-Strep. All the above were grown at 37°C in an 
incubator with 5% CO2. 
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Drugs used in the study 
The two PI3-K inhibitors, LY294002 and wortmannin (Calbiochem, San Diego, CA, 
USA) were used along with LY303511 (Alexis Biochemical, San Diego, CA, USA) 
to show that LY303511 is indeed a negative analogue of LY294002 and that it does 
not inhibit phosphorylation of Akt at Ser-473.  
A one- hour preincubation with LY303511, followed by addition of TRAIL (Biomol 
Research laboratories, Plymouth meeting, PA, USA) was shown to enhance TRAIL 
induced apoptosis in a synergistic manner. 
Pharmacological inhibitors/activators used in the study 
 
1. 2000 units/ml of catalase (Sigma Aldrich, St Louis, MO, USA) 
Catalase was freshly prepared by weighing out 2000 units/ml and dissolved in 
plain DMEM. 
 
2. 4μmol/l JNK inhibitor SP600125 (Sigma Aldrich, St Louis, MO, USA) 
SP600125 was prepared as a stock solution of 20 mM by dissolving it with 
DMSO. 
 
3. 10μmol/l p38 inhibitor SB202190 (Sigma Aldrich, St Louis, MO, USA) 
SB202190 was prepared as a stock solution of 100 mM by dissolving it with 
DMSO. 
 
4. 20μmol/l MEK inhibitor PD98059 (Sigma Aldrich, St Louis, MO, USA) 
PD98059 was prepared as a stock solution of 20 mm by dissolving it with 
DMSO. 
 
5. 50µmol/l caspase-8 inhibitor z-IETD-FMK (R&D systems, MN,USA) 
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6. 50µmol/l pan-caspase inhibitor z-VAD-FMK (R&D systems, MN,USA) 
7. 4µg/ml anti-DR4 (Alexis Biochemical, San Diego, CA,USA) 
8. 1µg/ml anti-DR5 (Alexis Biochemical, San Diego, CA,USA) 
9. Phorbol Myristate Acetate (PMA) (Sigma-Aldrich, St Louis, MO, USA) 
10. Hydrogen peroxide (Merck, NJ, USA) 
11. Bisindolylmalemide (Cell signaling, Beverly, MA, USA) 
12. EGTA-AM (Invitrogen, Molecular probes, Eugene, OR, USA) 
 
Determination of cell viability with crystal violet and MTT assay 
In a typical survival assay, SHEP-1 cells (0.8x104/ well) plated in 24-well plates for 
24 hours were exposed to LY30 (12.5, 25 and 50 μM), TRAIL (25, 50 and 100 
ng/ml), and a combination of the two (1 hour preincubation with LY30 followed by 
TRAIL for four hours). Cytotoxicity was determined by the crystal violet assay as 
follows. After drug exposure, cells were washed with 1X PBS (Phosphate Buffered 
Saline) and incubated for 20 minutes at room temperature with crystal violet solution 
(200 μl). The excess crystal violet solution was washed away with distilled water and 
the remaining crystals were dissolved with 20% acetic acid or 5X SDS. Viability was 
determined by absorbance at 595nm wavelength using an automated ELISA reader. 
Viability analysis following mono and combined treatment of SH-SY5Y, T98G and 
LnCAP cells were performed similarly by crystal violet assay. Preincubation of 
SHEP-1 cells with 2000units/ml of catalase, 4μmol/l JNK inhibitor SP600125, 
10μmol/l p38 inhibitor SB202190, 20μmol/l MEK inhibitor PD98059 50µmol/l of 
caspase-8 inhibitor zIETD-FMK or pan-caspase inhibitor zVAD-FMK, or death 
receptor blocking antibodies (4µg/ml anti-DR4 or 1µg/ml anti-DR5), or siRNA 
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mediated silencing of JNK and ERK expression was followed by respective 
treatments and crystal violet analysis accordingly.  Crystal violet solution is made by 
dissolving 0.75% crystal violet in 50% ethanol:distilled water with 1.75% 
formaldehyde and 0.25% Nacl and is stored at room temperature. 
 
Viability analysis for non-adherent Jurkat cells was done using MTT assay. 
Following drug exposure, cells were collected and 50 μl of the cell suspension was 
added to a 96-well plate. 50 μl of freshly made MTT (3-5 mg/ml in plain RPMI) was 
added to each well and incubated for 2-4 hours in dark. After incubation, the plate 
was spun at 3000 rpm for 15 min, the supernatant was carefully removed and the 
adhered crystals were dissolved in 200μl of a buffer per well. The buffer contains 
200μl DMSO + 10 μl Sorensen’s Glycine Buffer (0.1M Glycine, 0.1 mM NaCl, 
adjusted to pH 10.5 with 1M NaOH). The viability was determined by measuring 
absorbance at 570 nm wavelength using an automated ELISA reader. 
 
Determination of the tumor cell colony forming ability 
SHEP-1 cells (0.8x104/well) plated in 24-well plates for 24 hours were treated with 
TRAIL (25ng/ml) for 4 hours with or without a 1 hour pretreatment with LY30 
(25µm). They were then washed once with 1X PBS, counted and replated in to 
100mm petri dishes (1x104 cells per sample) under sterile conditions. This was 
followed by incubation at 37°C to allow colony formation for 10 days. After the 
indicated incubation time, they were washed once with 1X PBS and stained with 
crystal violet solution (1ml). Incubation with the dye for 20 minutes at room 
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temperature was followed by washing away the excess crystal violet solution with 
distilled water to visualize the clonogenic potential of the cells. 
 
Determining the reproliferation potential of cells 
SHEP-1 cells were plated, treated and harvested as is done for analyzing colony 
forming ability of cells. Following this, equal number (1 x 105) of cells were 
replated under sterile conditions in to three 6-well plates and incubated at 37°C for 
counting and visualization after 24, 48, 72 hours respectively. The cell count was 
done using the Bio-Rad TC10TM automated cell counter and the values obtained  
were tabulated. 
Morphological examination  
The effect of single-agent and combined treatment with LY30 and TRAIL was 
qualitatively analysed by morphological examination of SHEP-1 cells. The cell 
morphology was visualized by an Olympus bright-field microscope at 40X 
magnification. 
Propidium iodide (PI) staining for DNA fragmentation 
Cells were pretreated with LY30 for 1 hour and then exposed to TRAIL for 4 hours 
for quantitative analysis of apoptotic cell death in SHEP-1cells.  PI staining for DNA 
content analysis was performed in order to corroborate the results obtained for cell 
viability by crystal violet assay. SHEP-1 cells were permeabilised using 70% 
ethanol, followed by staining with 10μg/ml PI and 250μg/ml RNase A (Sigma 
Aldrich, St. Louis, MO,USA) dissolved in 1x PBS. At least 10000 stained cells were 
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acquired using a flow cytometer (Beckman Coulter, USA) using an excitation 
wavelength set at 488 nm and emission at 610 nm. The analysis of the captured 
events was done using the WinMDI software. The sub-G1 peaks on the histogram 
are representative of the apoptotic cells displaying fragmented DNA content.  
The PI stock solution (50X) was dissolved in sodium citrate buffer (38 mM) to a stock 
concentration of 0.5 mg/ml and kept in 4 °C and protected against exposure to light 
RNAse A was dissolved in 10 mM Tris-HCl (pH 7.5) and 15 mM NaCl to a stock 
concentration of 10 mg/ml and kept at -20 °C. PI: RNAse A solution was freshly 
prepared with 1/50 volume of PI and 1/40 volume of RNAse A stock solution in 1X 
PBS or 38 mM sodium citrate buffer. 
Determination of caspase activities 
SHEP-1 cells were incubated with TRAIL (50ng/ml) for 4 hours with or without 
preincubation with LY30 (25 µmol/l) for 1 hour. The cells were then washed with 1X 
PBS, resuspended in chilled cell lysis buffer (BD pharmingen, CA, USA), and 
incubated on ice for 10 minutes. This was followed by incubation with the standard 
reaction buffer (50 µl; 10 mmol/l HEPES, 2 mmol/l EDTA, 10 mmol/l KCl, 1.5 
mmol/l Mgcl2, 10 mmol/l DTT) and fluorogenic caspase-specific substrates (1µl; Ac-
VDVAD-AMC for caspase-2, DEVD-AFC for caspase-3, VEID-AFC for caspase-6, 
LETD-AFC for caspase-8 and LEHD-AFC for caspase-9; Alexis Biochemicals, San 
Diego, CA, USA) and incubation at 37°c for 1 hour. Enzymatic activity was 
determined by the relative fluorescence intensity upon cleavage of AMC or AFC at 
505 nm following excitation at 400 nm using a Tecan spectrofluorometer and 
analyzed using Megallan software. The fluorescence values obtained were calculated 
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relative to the protein concentration for each sample and plotted as fold increase in 
caspase activity of treated samples compared to untreated ones. 
Subcellular  - Mitochondrial fractionation  
Mitochondrial fractionation was performed by incubating cells for 20 minutes in 
extraction Buffer A on ice following indicated drug treatments. The cells were then 
homogenized with a dounce homogenizer 18 times on ice and the homogenates were 
centrifuged twice at 300g for 10min at 4°C. Supernatants were collected and 
centrifuged again at 12,000g for 20min at 4 °C. The supernatant now obtained is the 
cytosolic fraction and the pellet recovered was resuspended in RIPA lysis buffer and 
consisted of the mitochondrial fraction. The two fractions, cytosolic and 
mitochondrial were resolved on SDS-PAGE gels. Cyto c release to the cytosol from 
the mitochondria was compared with VDAC as a mitochondrial fraction loading 
control. Buffer A is comprised of 50 mM PIPES-KOH pH7.4, 220 mM mannitol, 68 
mM sucrose, 50 mM KCl, 5 mM EGTA, 2 mM MgCl2 and 1 mM DTT. Before use, 
this buffer was supplemented with protease and phosphatase inhibitors. 
Flow cytometric analysis of H2O2 production 
Intracellular concentration of H2O2 was determined by staining with the redox- 
sensitive dye 5-(and-6)-chloromethyl-2',7'-dichlorofluorescin diacetate (CM-
H2DCFDA; Molecular probes, Eugene, OR, USA), which is cleaved by esterases  
keeping it within the cell and becomes fluorescent upon oxidation by H2O2 and its 
free radical products. Following treatment with LY30, SHEP-1 cells were washed 
with 1X PBS, loaded with 5 µmol/l of the dye in serum-free medium and incubated 
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at 37°C for 15 minutes. The cells were washed with 1X PBS, resuspended in serum-
free medium and atleast 10,000 events were captured by flow cytometry using an 
excitation wavelength of 488nm. The histogram analysis was performed using the 
WINMDI software. 
SiRNA-mediated silencing of JNK, ERK and p38 
For total ERK, JNK or p38 knockdown using specific siRNA’s, SHEP-1 cells were 
plated in six-well plates for 24 hrs before transfection to obtain about 40% 
confluence the next day and the medium was replaced with antibiotic-free DMEM 
about 4 hours before commencing transfection. Transient transfections were 
performed using Dharmafect transfection reagent and 100nm of ERK1, ERK2, JNK 
or p38 smartpool siRNA (Dharmacon technologies, Lafayette, CO, USA) dissolved 
in opti-MEM (Invitrogen, San Diego, CA. USA). The control cells were transfected 
with scrambled non-targetting siRNA.  24 hrs after transfection, the media was 
replaced with complete DMEM and cells were incubated further for 24-48 hrs. 
Following which, SHEP-1 cells were treated with LY30 before assaying for protein 
expression by western blotting as well as the effect on DR4 and DR5 cell surface 
expression. 
Analysis of DR4 and DR5 surface expression 
SHEP-1 cells (2.5 x 105) were treated with LY30 as described and washed with 
FACS buffer (1X PBS + 0.5% FBS) after detachment of adherent cells with EDTA. 
Cells were then stained with the fluorochrome, phycoerythrin (PE)-conjugated 
mouse monoclonal anti-human  DR4 or DR5 (clone 69036 and 71908  respectively, 
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R & D systems, Minneapolis, MN, USA) for 45 minutes at 4oC according to 
manufacturer’s instructions before washing and resuspension in FACS buffer for 
flow cytometry using an excitation wavelength of 488. PE-conjugated mouse IgG2b 
was used as an isotype control and the obtained events were analysed by WINMDI 
software. 
Confocal imaging for PKC α and pERK 
SHEP-1 cells were plated on glass coverslips and treated with LY30 as indicated. 
Following fixing and permeabilization with 2% paraformaldehyde and 0.1% Triton 
X respectively, cells were blocked in PBS buffer (0.3 g BSA + 0.5% FBS+ 15ml 1X 
PBS) overnight to block non-specific protein binding. The cells were then probed 
with the primary antibody, anti-mouse PKC α (BD Pharmingen, San Diego, CA, 
USA) or anti-rabbit pERK (Cell signaling, Beverly, MA, USA) at 1:200 diluted in 
PBS buffer and incubated at room temperature in dark for 2-3 hours. This was 
followed by washing off the excess antibody and probing with secondary antibody, 
Alexa Fluor 488 or Alexa Fluor 594 (Invitrogen, San Diego, CA, USA) respectively 
for 1-2 hours. Following subsequent washing, the cells were carefully mounted on to 
microscope slides with mounting medium containing DAPI and visualized at 100 X 
magnification on an Olympus FV300 microscope using an UPlanFI 60X/1.25 
objective lens. The processed images were analysed using FV10-ASW 2.0 viewer 
software. 
Subcellular  - Nuclear fractionation  
Nuclear and cytosolic separation was performed by incubating cells in a hypotonic  
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buffer containing 10 mM HEPES, pH 7.5, 10 mM KCl, 1mM EDTA, 1 mM EGTA, 
1 mM DTT, 1 mM MgCl2, 5% glycerol supplemented with protease and phosphatase 
inhibitors and allowed to swell for 15 min. Cells were then lysed by adding Nonidet 
P-40 and the nuclei were pelleted by centrifugation at 15000 g for 3 min. The 
obtained supernatant was centrifuged at 15000 g for 5 min and stored as the 
cytoplasmic fraction. The nuclei were washed two times by centrifuging for 10 min 
at 1500 g in a modified hypotonic buffer that contains only 10 mM HEPES, pH 7.5, 
10 mM KCl, 1 mM DTT, 1 mM MgCl2.  The pellet was then resuspended in nuclear 
lysis buffer comprising of 20 mM HEPES, pH7.5, 0.4 M NaCl, 1 mM EDTA, 1 mM 
EGTA, 1mM DTT, 1 mM MgCl2, and 25% glycerol. The dissolved nuclei were 
incubated on ice for 15 min with intermediate vortexing and centrifuged at 15000 g 
for for 5 min. Supernatant was collected and stored as the nuclear fraction.  
Western blot analyses 
Total protein (60-100µg) was separated using 10-15% SDS- polyacrylamide gel 
(SDS-PAGE) depending on the molecular weight of the proteins to be probed for. 
Proteins which get separated on the gel based on their electrophoretic mobilities were 
transferred to a PVDF membrane and then blocked with 5% non-fat milk in TBST 
(Phosphate buffered saline with 0.5% Tween- 20).  
Primary antibodies used to probe for phosphorylated Akt Ser 473(p-akt);  
phosphorylated and total ERK1/2 (pERK  and tERK);  caspase-8;  DR5;  cytochrome 
c;  phosphorylated and total c-jun (p-c-jun and t-c-jun); Phosphorylated and total 
PEA-15 (pPEA-15 and tPEA-15);  phosphorylated MARCKS (pMARCKS) and total 
JNK 1/2 (tJNK) were obtained from Cell Signaling, Beverly, MA, USA.  
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phosphorylated JNK 1/2 (pJNK) was obtained from Calbiochem, San Diego, CA , 
USA;  phosphorylated and total p38 (pp38 and tp38), DR4, Bcl-2 and VDAC was 
obtained from Santa Cruz, CA, USA). β actin (Santa Cruz, CA, USA) was used as a 
loading control to indicate equal analysis of protein samples. Following 
immunoblotting with primaryantibodies, the membranes were probed with respective 
secondary antibodies conjugated with horseradish peroxidise (HRP) and bound 
immunocomplexes were visualized by the West Pico chemiluminescence substrate 
(Pierce, IL, USA) and captured on Kodak films. 
Buffers and reagents used for Western Blot analysis 
1. Protein extraction (obtaining cell lysate)  
The buffer used for protein extraction to obtain whole cell lysates for western 
blotting was the standard Radio Immuno Precipitation Assay buffer ( RIPA lysis 
buffer) constituting 50mM Tris HCl pH 7.5, 150mM NaCl, 1% v/v Nonidet P40, 
0.1%v/v SDS, 1mM EDTA. This buffer was supplemented with protease inhibitors 
(1mM PMSF, 10μg/ml Aprotinin, 20μg/ml Pepstatin A, 10μg/ml Leupeptin) and 
phosphatase inhibitors(1mM Sodium Fluoride(NaF), 1mM activated  Sodium 
orthovanadate (Na3VO4)) immediately before use.  
2. Measurement of protein concentration  
Following cell lysis, the amount of protein present in each sample was quantitated 
using Bradford assay. This colorimetric protein assay is based on the absorbance 
shift at 595 nm of the Coomassie Blue reagent (Pierce, IL, USA) of samples to be 
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measured and compared with protein standards. The concentration and absorbance of 
these protein standards as measured using a spectrofluorometer is plotted by linear 
regression on a standard protein curve and solving the equation for this line gives the 
protein concentration (μg/μl) of each sample. 
3. Laemmli loading Buffer   
Once the protein samples are quantitated and aliquoted, each sample is mixed with 
1/4 vol of 5x Laemmli loading Buffer + 1M DTT and boiled at 100 °C for 10 
minutes before loading. The Laemmli sample loading buffer comprises of  1M Tris-
HCl pH 6.8  - 4ml, 10% SDS - 1g , 20 % glycerol  - 2ml, 25% β-Me 2.5ml, 0.1 % 
Bromophenol Blue - 0.01g and topped with 1.5ml dH2O to make up to 10ml. 
4. Running Buffer 
To make a 10X running buffer, 30 g of Tris-base, 144 g of Glycine and 10g 
of SDS is mixed with 1 litre of dH2O. This buffer is diluted to 1X with dH2O to 
use for western blot analysis. 
5. Transfer Buffer 
A 1X Transfer buffer constitutes  5.4 g of Tris-base, 11.56 g of Glycine, 200 ml of 
methanol, topped up to a litre with dH2O. 
6. TBS 
TBS was prepared as 500 ml 1 M Tris HCl (pH 7.4) with 87.6 g of NaCl in 10L of 
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dH2O and stored at room temperature. TBST was prepared as 2 L TBS with 2 ml of 
Tween-20 and stored at room temperature. 
 




 4%   -  4 ml 
 
































8. Resolving/separating gel preparation 
 
Statistical analysis  
Data are expressed as mean ± SE. Statistical differences were determined by two-
way analysis of variance and student’s t test. A p value of <0.05 was considered 
significant.  
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PART 4 - RESULTS  
 
1.    LY30 AUGMENTS THE EFFICACY OF TRAIL IN A SYNERGISTIC MANNER AS 
EVIDENCED BY ENHANCED SENSITIZATON 
1.1   LY3O IS A STRUCTURAL ANALOGUE OF LY29 AND IS A NEGATIVE CONTROL 
FOR INHIBITION OF PI3-K ACTIVITY  
LY29 is a synthetic derivative of Quercetin, which competes with ATP to 
preferentially and reversibly bind to the ATP-binding pocket of PI3-K and many 
other related kinases, thereby inhibiting their activation. LY30 shares a high degree 
of structural similarity to its precursor LY29 (as shown in Figure 5A).  Despite the 
notable similarity in structure, a single atom substitution where the morpholino 
oxygen of LY29 is replaced with an amine group in LY30 renders it unable to bind 
to the ATP - binding pocket of PI3-K. Thus, LY30 is an inactive structural analogue 
of LY29 which doesn’t alter PI3-K activity and is popularly used as a negatory 
control for inhibition of PI3-K enzyme activity (Vlahos et al, 1994). To establish that 
LY30 indeed does not function as an inhibitor of the PI3-K - Akt pathway, the 
phosphorylation status of Akt was probed in cell lysates of SHEP-1 neuroblastoma 
cells. As expected, LY29 and Wortmannin (a fungal metabolite which is also a 
known potent inhibitor of the PI3-K survival pathway) completely blocked Akt 
phosphorylation at Ser473 whereas LY30 (25µmol/L) had no effect on the 
phosphorylation status of Akt in these cells (Figure 5B).  This forms the basis for 
future studies in this thesis on LY30 and its signaling mechanism, which can now be 
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Figure 5: LY30 does not inhibit PI3-K enzyme activity 
 
(A)   Molecular structures of Quercetin, LY294002 and   
LY303511   
(B)  Western blot analysis of the effect of 1 hr incubation 
with LY29 or LY30 (25µmol/L) or Wortmannin (200 
nmol/L) on Akt phosphorylation at Ser473 in SHEP-1 






1.1 PREINCUBATION OF TUMOR CELLS WITH  LY30  ENHANCES TRAIL-       
INDUCED CELL DEATH IN TUMOR CELLS 
 
Complete or partial resistance of tumor cells to TRAIL- mediated apoptosis has 
limited the use of TRAIL as a therapeutic modality. Given that pretreatment with 
compounds such as Quercetin, LY29 and LY30 can accelerate drug-induced cell 
death in tumor cells (Kim & Lee, 2007; Poh & Pervaiz, 2005), it was envisaged that 
LY30 may act as a sensitizer to augment TRAIL- mediated cell death.  To study this,  
tumor cells which are resistant to TRAIL to varying extents were  exposed  to 
increasing concentrations of LY30 alone, TRAIL alone or a combination of the two. 
Following pretreatment of SHEP-1 neuroblastoma cells for an hour with LY30 
followed by TRAIL treatment for four hours, the cell viability was assessed by 
crystal violet assay. SHEP-1 cells were moderately responsive to single-agent 
treatment with TRAIL (~10%, ~20% and ~40% reduction in the surviving fraction at 
25 ng/ml, 50 ng/ml and 100 ng/ml respectively) while treatment with LY30 (12.5, 
25, 50 or 100 µmol/L) alone did not induce any cell toxicity (Figure 6 A, B). Indeed, 
a combined treatment of SHEP-1 cells with LY30 and TRAIL had a significantly 
amplified effect as compared to mono treatment with LY30 or TRAIL alone. (~40% 
reduction in viable cells with LY30 25 µmol/L + TRAIL 50 ng/ml versus ~20% with 
TRAIL 50ng/ml alone (Figure 6 C). This enhancement of tumor cell sensitivity to 
TRAIL was not exclusive to SHEP-1 cells, as a combination of the two drugs, LY30 
and TRAIL, although at different doses resulted in increased responsiveness of a 
variety of tumor cell lines such as Jurkat leukemia, LnCAP prostate carcinoma, SH-
SY5Y neuroblastoma and T98G glioblastoma cells assessed by crystal violet or MTT 





              
 
              
 
Figure 6: Dose response of treatment with LY30, TRAIL and 
LY30+TRAIL  
 
(A, B) SHEP-1 cells (8 x10
4
 cells/well) were plated in 24-well plates 
for 24 hours and treated with either LY30 alone or TRAIL alone for 
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Figure 6: Dose response of treatment with LY30, TRAIL and 
LY30+TRAIL 
 
 (C) SHEP-1 cells (8 x10
4
 cells/well) were plated in 24-well 
plates for 24 hours and treated with a combination of LY30 and 
TRAIL (pretreated with LY30 for 1 hour prior to the addition of 
TRAIL). Four hours after TRAIL treatment, cell viability was 






  C 
 75 
 
      
 
                                          Morphological examination – LnCAP 
                         Ctrl                       LY30 - 25µmol/L        TRAIL -25 ng/ml      LY30 -25µmol/L  
                        +TRAIL - 25 ng/ml 
              
            
                
Figure 7: The combinatorial effect of LY30 and TRAIL is not 
restricted to SHEP-1 cells   
(A, B, C)  Cell viability was determined in tumor cell lines such as 
Jurkat, LnCAP, T98G and SH-SY5Y by crystal violet assay or MTT 
proliferation assay. A combined treatment shows enhanced 
sensitivity to TRAIL when preincubated with LY30. 
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1.2 SYNERGISTIC RESPONSE OF SHEP-1 CELLS WHEN TREATED WITH LY30 AND 
TRAIL IN COMBINATION 
One property of a drug that makes it additionally attractive to be used in combination 
therapy as a sensitizer is its ability to accelerate cell death induced by the executor 
drug without exhibiting any cytotoxicity on its own. As shown in the preliminary 
experiments, the sensitizer drug LY30 does not induce any cell death when used as a 
single-agent treatment in SHEP-1 cells and it only enhances execution of TRAIL-
mediated apoptosis. To better our understanding of the interaction between these two 
drugs, two similar statistical methods – Isobologram and Combination index (CI) 
which provide a qualitative and quantitative representation of the drug effects when 
used in combination were tabulated and charted from the obtained viability data.  
 
Isobologram analysis was done by plotting the dose response interactions at the IC25 
(inhibitory concentration 25%) level as a graph where the x and y axes represent 
doses of TRAIL and LY30 respectively.  The hypotenuse is the line of additivity, 
which represents the dose of each individual drug required to produce an effect like 
IC25.  As mentioned before and shown in Figure 6A, LY30 (up to 100 µmol/L) does 
not induce any cell death on its own and cell viability with TRAIL as a single agent 
treatment decreases viability by up to 25% at 50ng/ml. Hence the line of additivity is 
drawn beyond the 50 µmol/L point on the y axis for LY30 and at 50ng/ml on the x 
axis for TRAIL. The dotted line and dashed line represent the respective drug 
combination point which is the dose of the drugs in combination showing 25% 
inhibition of cell viability. Synergism between the two compounds is indicated as the 





                       
          
 
Figure 8: Statistical representation of synergistic 
drug interaction  
 
(A) Isobologram analysis representing the synergy 







Combination index (CI) is a quantitative representation of the viability data. It is 
calculated as a sum of the ratios of the dose of LY30 (x) or TRAIL (y) in 
combination (com)  that produces an effect such as IC25 to the dose of LY30 or 
TRAIL required as a single agent treatment (mono) to produce the same effect. 
Combination index is tabulated as follows: 
Drug xcom               Drug ycom 
Drug xmono          Drug ymono 
When z, the sum of these ratios equals 1, it signifies an additive effect between the 
two drugs. Synergism is indicated when z is less than 1 and antagonism when it is 
more than 1. The combination index for the indicated two drug combinations of 
LY30 and TRAIL is 0.325 and 0.5 respectively which is less than 1 and thus, gives 








Figure 8:Statistical representation of synergistic 
drug interaction   
 
 (B) The Combination index was plotted to indicate 
synergy between the two drugs at various doses.   
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2. CORROBORATING THE ABILITY OF LY30 TO ACT AS AN EFFICIENT 
SENSITIZER TO TRAIL-INDUCED APOPTOSIS 
 
2.1  INCREASED DNA FRAGMENTATION AND MORPHOLOGICAL CHANGES     
       OBSERVED BY COMBINED TREATMENT 
 
 Having shown to be efficient and synergistic, a combination dose of 25µmol/L LY30 
and 25ng/ml or 50ng/ml TRAIL was chosen for most of the following experiments in 
the moderately TRAIL resistant cell line SHEP-1 neuroblastoma. These encouraging 
observations so far led to the next step of validating the viability results to further 
understand the type of cell death that was induced.  To do so, DNA fragmentation 
which is one of the characteristic hallmarks of cells undergoing apoptosis was 
assayed by staining cells with Propidium Iodide - RNAse (PI-RNAse). The 
fluorescence emitted following intercalation of PI with the fragmented DNA of 
apoptotic cells was measured by flow cytometry. Consistent with the preliminary 
results obtained for cell viability, SHEP-1 cells stained with PI-RNAse also showed 
strong sensitizing effect of LY30 on TRAIL-induced apoptosis (Figure 9). Cells 
treated with LY30 alone were similar to control cells in their cell cycle profile while 
cells treated with LY30 and TRAIL showed an increase in sub-diploid fraction (sub-
G1; 43% ) vs. TRAIL alone (sub-G1; 22%) which is commensurate with the data in 
Figure 6C. Another classical hallmark of apoptosis is the morphological changes that 
occur due to blebbing of the cell membrane. Examination of cell morphology showed 
significant formation of membrane blebs upon LY30+TRAIL treatment (Figure 10 
panel d) as compared to TRAIL alone (Figure 10 panel c).  
 
  




                      
Figure 9:  Cell cycle profiles obtained by PI staining  
indicating DNA fragmentation   
 
Following treatment of SHEP-1 cells with TRAIL (50 
ng/ml) for 4 hours with or without pre-treatment with 
LY30 (25 µmol/L) for 1 hr, cells were stained with 









                             
 
Figure 10: Photomicrograph of SHEP-1 cells 
following  treatment 
         Panel a: control (untreated cells) 
         Panel b: Treated only with LY30 25 µmol/L  
         Panel c: Treated only with TRAIL 50 ng/ml 
         Panel d: Combined treatment with LY30 25 µmol/L  
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2.2 TREATMENT WITH LY30 + TRAIL INCREASED CASPASE ACTIVATION LEADING 
TO INITIATION OF THE APOPTOTIC CASCADE  
 
To obtain further understanding of the signaling pathway regulating the death 
amplification activity of LY30, the involvement of caspase proteases was 
investigated.  Since LY30 does not induce any cytotoxicity, it was expected to 
observe that single-agent treatment with LY30 (25µmol/L) does not induce caspase 
activation. As shown, SHEP-1 cells are moderately sensitive to TRAIL and hence 
exposure of cells to TRAIL (50 ng/ml) resulted in activation of caspases 8, 2, 6, 9, 
and 3 to some extent while preincubation of cells with LY30 followed by TRAIL 
treatment increased activation of caspases 8, 2, 9, and 3 significantly (Figure 11). 
Furthermore, while the overall expression of caspase 8 did not change appreciably 
upon exposure to either LY30 or TRAIL or their combination, TRAIL-induced 
processing of pro-caspase 8 was markedly enhanced in cells treated with LY30 and 
TRAIL (Figure 12 A).  The increase in LY30+ TRAIL-induced caspase 8 processing 
and activity was accompanied by a significant increase in caspase 9 activation and 
release of cytochrome c to the cytosol indicating possible permeabilization of the 
mitochondrial outer membrane (Figure 12 B). Most importantly, the presence of the 
caspase-8 tetra-peptide inhibitor Z-IETD-FMK (50 µmol/L), like the  pan-caspase 
tetra-peptide inhibitor Z-VAD-FMK (50 mol/L), not  only blocked TRAIL-
signaling, but also completely abrogated  (p value<0.01) the sensitizing effect of 
LY30 on TRAIL-induced cell death, thus questioning the extent of involvement of 
the mitochondrial pathway (intrinsic) in the death receptor-initiated (extrinsic) death 
signaling initiated by LY30 (Figure 13). 
  








Figure 11: LY30 and TRAIL treated cells show 
enhanced caspase activation   
 SHEP-1
 
cells were treated with TRAIL (50 ng/ml) in the 
presence or absence of LY30 (25 µmol/L) and 50µg protein 
was incubated with caspase-specific substrates (1 µL; Ac-
VDVAD-AFC for caspase-2, DEVD-AFC
 
for caspase-3, 
VEID-AFC for caspase-6, LETD-AFC for caspase-8 and 
LEHD-AFC for caspase-9 and measured for activity after 4 
hours. 
  




Figure 12: Enhanced caspase 8 processing and release of 
apoptogenic factors upon combination treatment   
SHEP-1 cells about 90% confluence were treated for 4 hours with 
LY30 (25 µmol/L), TRAIL (50 ng/ml), or 50 ng/ml TRAIL following 
1 hour pretreatment with 25µmol/L LY30: 
(A) 100 µg of total protein obtained was subjected to western blotting 
and checked for caspase-8 processing.  
(B) Release of cytochrome c from the mitochondria to the cytosol was 













Figure 13: Inhibition of caspase activation 
rescues cells from TRAIL and LY30+TRAIL 
mediated apoptotic cell death  
Cells were treated with TRAIL (50 ng/ml) for 4 
hours with or without 1 hour pretreatment with 
LY30 (25µmol/L) ± Z-IETD-FMK or Z-VAD-
FMK (50µmol/L) and the cell viability was 
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2.3  REPROLIFERATION POTENTIAL AND COLONY FORMING ABILITY ARE  
MARKEDLY REDUCED FOLLOWING TREATMENT WITH LY30 AND TRAIL 
While the preceeding experiments have established to a considerable extent that a 
combination of LY30 and TRAIL induces apoptotic cell death via caspase activation 
in a synergistic manner in short-term viability assays, it was of particular interest to 
examine the effect of this combination on cell growth over time. The approach used 
to study this was to treat cells ( with LY30 25µmol/L alone, TRAIL 25 ng/ml alone 
or a combination of the two as is done in a typical cell viability assay), following 
which the cells were replated at a lower density and grown in a drug-free 
environment for a longer period of time. Assessing the ability of cells to re-grow 
would answer if the cells regain their capacity to proliferate or to form colonies upon 
cessation of drug treatment.  The capacity of the cells to reproliferate was examined 
by cell counting at 24, 48 or 72 hours post reseeding. Figure 14 shows a quantitative 
and visual observation clearly showing that the cells are unable to regain their 
potential to proliferate upon combined treatment which substantiates the observed 
decline in cell viability.  Alternatively, the cells were continued to grow in 100 mm 
Petri dishes and allowed to form colonies for 10-14 days after which they were 
stained with crystal violet as described.  It is indeed significant that the combined 
treatment of the two drugs in SHEP-1 cells completely inhibits their efficiency to 
form colonies (Figure 15).  On that note, it should be considered that cytotoxicity is 
most often lower in a short term exposure and in respect to this system; crystal violet 
staining can give a higher estimate for cell survival. Hence, the TRAIL concentration 
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Figure 14:  Effect of treatment with LY30, TRAIL and their 
combination on the reproliferation  potential of SHEP-1 cells   
SHEP-1 cells (8 x 10
4 
cells/well) were exposed to 25 ng/ml of 
TRAIL for 4 hours in the presence or absence of 25µmol/L 
LY30. Following the treatment period, cells for each treatment 
were counted and reseeded in to 3 separate 6-well plates to be 
assayed for their viability every 24 hrs, up to 72 hrs. 
Accompanying figure shows a visual representation of cell 







CTRL LY30  TRAIL LY30+TRAIL 
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Figure 15: Assessing the colony forming ability 
following single agent and combined treatment  
SHEP-1 cells (8 x10
4 
cells/well) were exposed to 25 
ng/ml of TRAIL for 4 hours in the presence or 
absence of 25µmol/L LY30. Following the treatment 
period, 20,000 cells for each treatment were 
reseeded in to 100 mm petri dishes and allowed to 
form colonies over 10 to 12 days, after which they 
were stained with crystal violet to show colony 
formation. Representative data is as shown. 
  
                                                                                                                                   89 
3.  EVALUATING THE POSSIBLE ROLE OF ROS AS AN UPSTREAM SIGNALING 
MOLECULE 
3.1   LY30 PRODUCES ROS IN A EXPOSURE AND TIME- DEPENDENT MANNER  
 
Taking a clue or two from the structural characteristics and previous studies on 
LY30, it is then most probable that LY30 produces intracellular ROS as an upstream 
signaling molecule in SHEP-1 neuroblastoma cells. Oxidation of the redox sensitive 
probe CM-H2DCFDA in the presence of ROS generates a fluorescent oxidized 
product. This emitted fluorescence is a measure of ROS produced in the cells which 
can be detected by fluorescent-activated cell sorting (FACS) and analyzed by flow 
cytometry.   
In agreement with previous related studies in prostate carcinoma cells, incubation of 
SHEP-1 cells with increasing doses of LY30 resulted in the production of ROS in a 
dose-dependent manner. In addition, exposure of SHEP-1 cells to LY30 resulted in a 
significant time kinetic increase in DCF fluorescence as early as 5 minutes (Figure 
16, 17).  From a signaling perspective, although LY30 is the drug that is pretreated 
and produces ROS at early time points, it is also important to examine if TRAIL 
could produce ROS as it can potentially influence and contribute to ROS production 
by LY30 seen at later time points. It is evident from the obtained data that there is no 
increase in DCF fluorescence upon incubation of cells with TRAIL (50 ng/ml) for 
the indicated time points, as early as 5 minutes, up to 2 hours (Figure 18). This 
clearly eliminates the role of TRAIL in ROS production, convincingly pointing to the 
idea that ROS production in this system is exclusive to LY30. 
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        Figure 16: LY30 produces ROS in a dose dependent manner  
A bar chart representing the mean value of CM-H2DCFDA 
fluorescence following exposure of SHEP-1 cells to increasing 
concentrations of LY30 (25µmol/L) at 30 minutes and a 
corresponding representative histogram. 
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    Figure 17: Time kinetics of ROS production by LY30  
A bar chart representing the mean value of CM-H2DCFDA 
fluorescence following exposure of SHEP-1 cells to LY30 
(25µmol/L) for varying amounts of time and a corresponding 
representative histogram. 
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Figure 18: Time kinetics of ROS production by TRAIL 
A bar chart representing the mean value of CM-H2DCFDA 
fluorescence following exposure of SHEP-1 cells to TRAIL 
(50 ng/ml) for different time points and a corresponding 
representative histogram. 
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3.2   PREINCUBATION OF CELLS WITH CATALASE ABROGATES INCREASE IN ROS 
AND ENHANCEMENT OF CELL DEATH  
 
Having observed that SHEP-1 cells produce ROS, the next experimental setup was 
conceptualized to get a better insight into the relevance of ROS production by LY30.  
Based on previous work and ongoing studies, it was hypothesized that the ROS 
produced upon exposure to LY30 could most likely be the “apoptotic ROS”- 
hydrogen peroxide (H2O2) which is detected by the probe, CM-H2DCFDA.  In order 
to validate this, SHEP-1 cells were preincubated with the H2O2 scavenger catalase 
(1000 units/ml and 2000 units/ml) for one hour alone as control or one hour prior to 
treatment with 25µmol/L LY30 to lower H2O2 levels.  It was reassuring to see that 
the increase in DCF fluorescence produced by LY30 was reduced to almost basal 
levels when cells were preincubated with catalase.  A representative histogram 
following flow cytometry analysis and the corresponding geometric mean of 
fluorescence is plotted in Figure 19. There always is a possibility that pleiotropic 
flavanoids like LY30 activate or inactivate signaling molecules and cellular 
pathways without it bearing any significance to the mechanism of action under study. 
Therefore, the question that now needed to be addressed was if this H2O2 produced 
had any functional relevance in terms of cell death.  It was indeed of paramount 
significance to the following work in this thesis to see that LY30-induced increase in 
the sensitivity of SHEP-1 cells to TRAIL was significantly (p value<0.05) inhibited 
in the presence of catalase. This observation underscores the involvement of 
intracellular H2O2 as a crucial regulator in the TRAIL sensitizing effect of LY30 
(Figure 20).   
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 Figure 19: Preincubation with catalase inhibits ROS produced by LY30 
   
SHEP-1 cells were treated with LY30 (25 µmol/L) for 30 minutes in the 
presence or absence of catalase (2000 units/ml) and loaded with CM-
H2DCFDA (5 µmol/L) for 15 minutes. Intracellular H2O2 generated was 
indicated by the shift in fluorescence as detected by flow cytometry. Above 










Figure 20: Catalase pretreatment abrogates cell death 
enhanced by LY30  
 
SHEP-1 cells (2.0 x 10
4
/well) were plated in 96-well plate for 24 
hours and treated with TRAIL (50ng/ml)  LY30 (25 µmol/L) 
for 4 hours in the presence or absence of catalase (2000 
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4. SURMISING THE POSSIBLE DOWNSTREAM  SIGNALING CASCADE INITIATED 
BY LY30 
 
4.1    INCREASE IN EXPRESSION OF ACTIVATED MAPKs FOLLOWING EXPOSURE TO 
LY30 AT EARLY TIME POINTS 
ROS species like H2O2 are transiently produced in various cellular systems and their 
main role is to initiate signal transduction processes by interacting and modifying 
proteins that can influence cell fate (Shlomai, 2010). Having linked the sensitizing 
effect of LY30 to intracellular H2O2 production, it was logical to assume that a 
signaling cascade known to be activated by stress triggers such as H2O2 would be 
involved as a downstream effector pathway in the sensitizing effect. One such 
evolutionarily conserved redox- regulated signaling pathway is the MAPK pathway.  
Phosphorylation of MAPKs serves as a marker of its activation which can be 
detected by antibodies specific to each of the phosphorylated forms. To investigate 
the likely role of MAPKs, SHEP-1 cells were exposed to LY30 (25µmol/L) from 15 
minutes up to 120 minutes. This was followed by western blot analysis of the 
phosphorylated and total forms of the three MAPKs - p38, JNK, or ERK.  The result 
observed was a good lead in this study as exposure to LY30 for as short as 15 
minutes resulted in phosphorylation mediated activation of all the three MAPKs, 
with very similar activation kinetics (Figure 21); which peaked at 15 to 30 min and 
returned to basal levels within 2 hours of treatment. This early and transient increase 
of activated MAPKs with LY30 treatment was intriguing and with this in mind, 
further assessment of their role in augmenting TRAIL induced apoptosis was 
pursued. 
  




     
Figure 21: Time course of MAPK activation  
SHEP-1 cells at ~90% confluence were treated 
with LY30 (25µmol/L) for up to 120 minutes. 
Activation of p38, JNK and ERK was detected 
by western blotting using antibodies specific for 
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4.2  MAPK ACTIVATION BY LY30 PLAYS A SIGNIFICANT ROLE IN AUGMENTING 
TRAIL-MEDIATED CELL DEATH AND OCCURS DOWNSTREAM OF H2O2 
PRODUCTION 
An ephemeral activation of MAPKs rather than a sustained one which may or may 
not be redox-regulated was observed in Figure 21. The activation of MAPKs was 
chosen to be studied after the observation that LY30 produced H2O2 and was 
specifically looked at as a ROS - target protein. However, ascertaining that 
simultaneous production of H2O2 and MAPK is not just circumstantial in this system 
and to confirm that H2O2 produced by LY30 is indeed the regulator of MAPK 
activation in SHEP-1 cells became the next aim of this study.  
The pursuable approach was to use the H2O2 scavenger catalase to examine the effect 
of scavenging H2O2 on LY30 mediated activation of MAPKs. To do so, SHEP-1 
cells were treated with LY30 (25µmol/L) for 30 minutes in the presence or absence 
of catalase (2000 units/ml) and activation of the three MAPKs - p38, JNK and ERK 
was detected by western blot analysis.  Proving that the study was heading in the 
expected direction was data showing that lowering H2O2 levels using catalase 
significantly blocked LY30-induced phosphorylation of p38, ERK and JNK (Figure 
22). Thus, having confirmed that H2O2 regulates MAPK activation, the obvious 
apprehension was that the activation may be occurring as a response of cells to the 
trigger. This was addressed and the critical role of activated MAPKs in enhancing 
TRAIL-induced cell death by LY30 was ascertained using pharmacological 
inhibitors to MAPKs. 
 
  




                             
Figure  22:  Corroborating redox regulation of MAPK 
SHEP-1 cells were treated with LY30 25µmol/L ± catalase 
2000units/ml or LY30 25µmol/L± MAPK inhibitor (SB202190 
10µmol/L, PD98059 20µmol/L or SP600125 4 µmol/L) for 30 
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SHEP-1 cells were pretreated with the JNK inhibitor SP600125 (4 µmol/L), p38 
inhibitor SB202190 (10 µmol/L), or MEK inhibitor PD98059 (20 µmol/L) for 1 hour 
before the addition of LY30 alone, TRAIL alone or LY30+TRAIL. Whereas, the 
presence of MAPK inhibitors did not affect cellular response to TRAIL alone (Figure 
23 A) or LY30 alone (Figure 23 A), it was encouraging to see that either inhibition of 
JNK or ERK (via MEK) significantly blocked LY30- induced increase in sensitivity 
of SHEP-1 cells to TRAIL (Figure 23 B).  
Of note, is the result that inhibition of p38 by SB202190 was unable to rescue cells 
from the sensitizing effect of LY30 which highlights the role of only JNK and ERK 
in determining cell fate.  The cells were also treated with the MAPK inhibitors as 
control and the specific effect of each inhibitor on the respective MAPK was 
confirmed by western blotting (Figure 22).           
5.  ASSOCIATING H2O2 PRODUCTION AND ERK REGULATION 
         5.1   ACTIVATED ERK TRANSLOCATES TO THE NUCLEUS  
Together with its activation, the intracellular localization is an important indicator of 
MAPK function as it determines which substrate protein becomes available to 
activated ERK for downstream activation. To either ratify or eliminate the possibility 
that LY30 altered cellular compartmentalization of ERK along with activating it, 
SHEP-1 cells treated with or without LY30 were visualized by confocal microscopy 
after probing with anti-rabbit phospho-ERK (primary antibody), Alexa Fluor 594 
labelled with red fluorescence (secondary antibody), followed by mounting with DAPI 
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Figure 23: Examining the effect of pharmacological inhibition of 
MAPK on cell viability   
(A, B) SHEP-1 cells (2.0 x 10
4
/well) were plated in 96-well plate for 24 
hours and treated with TRAIL (50 ng/ml) or LY30 (25 µmol/L) alone or a 
combination of the two for 4 hours with or without 1 hour prior exposure 
to JNK inhibitor SP600125 (4 µmol/L), p38 inhibitor SB202190 (10 
µmol/L), or MEK inhibitor PD98059 (20 µmol/L) and cell viability was 
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 (a fluorescent stain that strongly binds DNA and thus represents the nucleus in blue). 
Incidentally, activated ERK was seen to be co-localizing with the nucleus upon 
treatment with 25µmol/L LY30 for 30 minutes (Figure 24 A). This observation was 
confirmed by western blotting of lysates following cellular fractionation to obtain 
nuclear and cytosolic separation after LY30 treatment (Figure 24 A, B).  An increase 
in phosphorylated form of ERK in the nuclear fraction where PARP and CuZnSOD 
serve as loading controls for the nuclear and cytosolic fractions respectively was 
observed.   
 
5.2 PEA-15 IS PHOSPHORYLATED IN A SUSTAINED MANNER AND PKC IS 
MEMBRANE LOCALISED UPON TREATMENT WITH LY30 
 
An extensive literature search over plausible regulators of intracellular ERK 
localization particularly brought to light one novel phosphoprotein, PEA-15 that acts 
as a downstream scaffold protein that aids ERK in activating its target proteins, 
mainly RSK2.  Perhaps, the main reason for considering it is because of its relevance 
to two aspects of this study - sensitization of tumor cells to TRAIL as well as 
controlling subcellular localization of ERK by physically interacting with it so as to 
keep it sequestered in the cytosol.  
 
In Figure 24 B, along with the observation that activated ERK is localised to the 
nucleus, it was also observed that PEA-15 is primarily localized into the cytosol and 
that there is a slight increase in phosphorylated PEA-15 at Ser104 upon LY30 
(25µmol/L) treatment for 30 minutes. There at two conserved sites in the C-terminal  
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 Figure 24: Localization of activated ERK in the nucleus  
 
(A) SHEP-1 cells treated with or without 25 µmol/L LY30 for 30 
minutes  were analysed by confocal microscopy which reveals that 
activated ERK (red fluorescence) is localized in the nucleus (blue 
fluorescence) (B) Nuclear fractionation of SHEP-1 cells with and without 
treatment with LY30 indicating increased pERK localization in the 
nuclear fractions. 
 
Control LY30 - 25 μM 
A 
B 
 Control     LY30           Control    LY30 
    Cytosol                           Nucleus 
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tail of PEA-15 that can be phosphorylated – Ser104 and Ser116.  The focus in this 
study is on Ser104 since phosphorylation at this site is associated with its ability to 
regulate localization of ERK (Formstecher et al, 2001; Hill et al, 2002; Krueger et al, 
2005). In order to affirm the above observation, SHEP-1 lysates were subjected to 
western blot analysis and probed for the phosphorylated form of PEA-15 at Ser104 
(Figure 25A). The results indicate that there certainly is an early and sustained 
phosphorylation of PEA-15 at this residue. This was indeed an interesting 
observation and before any further hypothesis could be drawn on this novel protein, 
it was important to substantiate previously studied aspects of this protein. Thus, the 
next step was to examine if the upstream regulator of PEA-15 phosphorylation at 
Ser104 is PKC mediated as shown in prior studies (Araujo et al, 1993; Kubes et al, 
1998). Since PKC has many different isoforms, preliminary studies to ascertain 
activation of PKC was done by studying the activity status of one of the most 
commonly studied conventional isoform of PKC, PKCα. SHEP-1 cells were stained 
with anti-mouse PKCα (primary antibody), Alexa Fluor 488 which is a green-
fluorescence dye conjugate (secondary antibody) and mounted with DAPI for 
staining the nucleus, followed by visualization using confocal microscopy. The 
observation that PKCα is membrane localized in response to LY30 and PMA (PKC 
activator that serves as a positive control) is indicative of its activation and these 
encouraging results led to further studies on understanding regulation of PEA-15. 
 
5.3 UNDERSTANDING THE ROLE OF PKC AND ROS IN REGULATING 
PHOSPHORYLATION OF PEA-15 
 
To validate the significance of this activated PKCα as an upstream kinase regulating 
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Figure 25: Phosphorylation of PEA-15 at Ser 104  
(A) SHEP-1 cells were treated with LY30 (25µmol/L) for up to 2 hours. 
Activation of PEA-15 was detected by Western blotting using specific 
antibodies for total as well as phosphorylated form. (B) SHEP-1 cells 
were treated with different doses of LY30 or PMA (50 μM) for 15 
minutes, following which they were fixed, permeabilised, stained with 
the primary antibody, anti-PKCα; the seconday antibody Alexa Fluor 




pPEA-15 –Ser 104 
Total PEA-15 
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phosphorylation of PEA-15, SHEP-1 cells were treated with PMA that served as a 
positive control, with LY30 alone or a combination of LY30 with few known PKC 
inhibitors. The lysates were analysed by western blotting and probed for 
phosphorylated PEA-15 and MARCKS.  MARCKS is an important target protein of 
activated PKC (Aderem, 1992; Taniguchi et al, 1994) which was checked for its 
phosphorylaton status as an general indicator of PKC activation by LY30. 
Surprisingly, LY30 mediated phosphorylation of both PEA-15 and MARCKS was 
specifically inhibited by the PKC inhibitor Bis I and not by Gö6976 or Staurosporine 
(Figure 26 A). The only possible explanation is the preferential inhibition of certain 
isoforms of PKC by these inhibitors and is discussed in the later part of the thesis. 
Most strikingly, similar to LY30, exogenous addition of H2O2 increases PEA-15 
phosphorylation while lowering H2O2 levels by preincubating cells for an hour with 
2000 units/ml of catalase abrogates phosphorylation of PEA-15 induced by LY30 at 
Ser104 (Figure 26 B).  
 
Furthermore, the data obtained in Figure 24 was corroborated when SHEP-1 cells 
treated with LY30 (25µmol/L) in the presence or absence of Bis I (1 µM) were 
visualized by confocal microscopy wherein cells were stained with anti-rabbit 
phospho-ERK (primary antibody), Alexa Fluor 594 labelled with red fluorescence 
(secondary antibody) and mounted with DAPI. The results indicate that this novel 
protein PEA-15 might be a factor that regulates ERK localization and function in 
SHEP-1 cells. Thus, as activation of ERK is a result of H2O2 production as shown in 
the initial part of the thesis, it is conceivable that a crosstalk might exist between the 
produced H2O2 and activated PKC which is then responsible for phosphorylation of 
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Figure 26: Phosphorylation of PEA-15 at Ser 104 is regulated by PKC and H2O2 
(A) SHEP-1 cells pretreated with the PKC inhibitors Staurosporine (5, 10, 20 µM), 
Gö6976 (10µM) or Bis I (0.5, 1 µM) were treated with 25µmol/L LY30 for 30 
minutes and analysed by western blotting to observe phosphorylated forms of PEA-
15 and MARCKS.  
(B) Preincubation of SHEP-1 cells with either the PKC inhibitor Bis I (1µM) or 

























Figure 27:  Corroborating role of PKC in ERK localization  
Following treatment with LY30 with or without pretreatment 
with Bis I (1µM), SHEP-1 cells were fixed, permeabilised and 
stained with anti-rabbit pERK primary antibody followed by 
Alexa Fluor 594 secondary antibody and DAPI as indicated 









      LY30                  Bis I + LY30 
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PEA-15. This subsequently may allow activated ERK to localize to the nucleus. 
 
5.4   SILENCING PEA-15 SENSITIZES CELLS TO TRAIL  
PEA-15 has been shown to play an important role in TRAIL signaling and most 
studies highlight its anti-apoptotic role as it contains a DED which helps it to interact 
with components of the DISC, thus being able to directly regulate TRAIL- induced 
apoptosis (Condorelli et al, 1999; Kitsberg et al, 1999; Renault et al, 2003). With 
respect to SHEP-1 cells, silencing PEA-15 followed by determination of cell 
viability shows that inhibiting PEA-15 sensitizes cells to TRAIL to a similar extent 
as LY30. However, since PEA-15 can directly regulate sensitivity to TRAIL at the 
level of the DISC, silencing PEA-15 probably represents a more independent and 
general effect of PEA-15 protein inhibition which may be different from its 
phosphorylation mediated regulation of ERK localization. In addition, studying a 
signaling cascade requires constant questioning and linking of upstream signals with 
downstream effector pathways. Although it was observed in Figure 26 B that 
preincubation of SHEP-1 cells with catalase prevents phosphorylation of PEA-15 by 
LY30, H2O2 levels after PEA-15 silencing was studied to understand this novel 
protein better and to ascertain that it does not regulate production of H2O2. The 
results show that silencing PEA-15 did not perturb H2O2 production by LY30, thus 
eliminating the possibility that PEA-15 acts upstream of ROS production. The 
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Figure 28: Effect of silencing PEA-15 on call viability and H2O2 production 
 
 48 hours after SHEP-1 cells were transfected with PEA-15 siRNA  
(A)  they were treated with LY30 (25µmol/L), TRAIL (50 ng/ml) and a 
combination of the two and viability was measured by crystal violet assay.  
(B) they were treated with LY30 (25µmol/L) and assayed for ROS production by 
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                    +TRAIL 
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6.  AFFIRMING DEATH RECEPTOR UPREGULATION AS A MECHANISM FOR  
ENHANCED SENSITIZATION TO TRAIL 
 
6.1  EFFICIENT EXECUTION OF TRAIL- INDUCED APOPTOSIS BY ACTIVATION    
   OF THE EXTRINSIC PATHWAY IS REGULATED BY H2O2 
 
Now, the quest was to identify the process that actually allows H2O2 -initiated 
MAPK activation to be translated in to an apoptotic signal. Although activation of  
MAPK was shown to be an important upstream signal heightening TRAIL- induced 
apoptosis in SHEP-1 neuroblastoma cells, the most crucial event in this apoptotic 
cascade initiated by LY30 will be one that will ultimately allow TRAIL to be more 
efficient in inducing caspase 8 activation and thereby enhancing apoptosis. A little 
dwelling on the topic lead to the understanding that similar to other ligands in the 
TNF superfamily to which TRAIL belongs to; its efficiency is directly proportional 
to the number of cognate cell surface death receptors to which it can ligate. Thus, it 
was rational to believe that LY30 might signal for increase in the expression of death 
receptors and thus allow for enhanced sensitivity when bound by its ligand, TRAIL. 
 
The first step was to decipher if the TRAIL death receptors – DR4 and DR5 were 
functionally expressed. To understand this, death receptor stimulation was inhibited 
by pretreatment of SHEP-1 cells with anti-DR4 and/or anti-DR5 neutralizing 
antibodies and the assumption was validated by the results obtained. Indeed, either of 
the receptors significantly rescued cell death induced by TRAIL alone and 
LY30+TRAIL, while simultaneous blocking of both DR4 and DR5 completely 
rescued SHEP-1 cells from the sensitizing effect of LY30 on TRAIL-induced 
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apoptosis (Figure 29). Although this experiment does not help to answer if LY30 
increases death receptor expression, it certainly highlights the role of TRAIL death 
receptors in this study of LY30.  
 
To further examine the role of mitochondria either in H2O2 production or in 
activating downstream effector proteins that culminate to sensitize cells to TRAIL, 
an antiapoptotic protein that could inhibit the mitochondria from participating in the 
cell death process was transiently overexpressed. SHEP-1 cells were transfected with 
1 µg of Bcl-2 protein for 48 hours, which was followed by western blot analysis for 
determining Bcl-2 protein expression and crystal violet assay following indicated 
treatments for viability analysis. Interestingly, it was observed that transient 
overexpression of Bcl-2 was not able to rescue the cells from the sensitizing effect of 
TRAIL or LY30+TRAIL (Figure 30). Although, this does not eliminate the 
possibility that the mitochondria is involved in the signaling or cell death process via 
other antiapoptotic Bcl-2 family proteins, this data diminishes the possible role of the 
mitochondria  in apoptotic signaling of TRAIL enhanced by LY30 in SHEP-1 cells.  
 
6.2  INCREASE IN DEATH RECEPTOR LEVELS IS REGULATED BY H2O2  
Considering the results obtained, it’s imperative that the logical step ahead was to 
examine cell surface receptor levels in cells following LY30 treatment. It was indeed 
as expected as exposure of SHEP-1 cells to LY30 resulted in a time-dependent 
increase in the total cellular expression of both DR4 and DR5 at the protein level as 
observed by western blotting of lysates of SHEP-1 cells (Figure 31). 
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Having seen that H2O2 production regulates MAPK activation and enhanced cell 
death in this system, it was evident that it plays a crucial role in augmenting TRAIL-
induced cell death. However, to provide further confirmation of H2O2 mediated 
regulation of death receptor signaling hierarchy, the effect of scavenging H2O2 (2000 
units/ml of catalase) on the cell surface expression of DR4 and DR5 was 
investigated. Phycoerythrin-conjugated anti-DR4 or anti-DR5 was used to stain cells 
following treatment with LY30 (25µmol/L) and subjected to flow cytometric 
analysis. The obtained results clearly show the substantial increase in surface 
expression of the TRAIL receptors, DR4 and DR5. More importantly, this increase 
in receptor expression was completely inhibited by catalase (Figure 32 A, B), thus 
implicating H2O2 as an important effector molecule in LY30-induced death receptor 
enhancement and TRAIL sensitization.  
 
6.3    PHARMACOLOGICAL INHIBITION OR KNOCKDOWN OF JNK OR ERK      
BLOCKS LY30-INDUCED UPREGULATION OF DR4 OR DR5, RESPECTIVELY 
 
Given that LY30 activates a signaling cascade that regulates both MAPK activation 
and death receptor upregulation, it was curiosity that led to investigating the link 
between the two.  To do so, SHEP-1 cells were exposed to the JNK inhibitor 
SP600125 (4µmol/L), the p38 inhibitor SB202190 (10µmol/L), or the MEK inhibitor 
PD98059 (20µmol/L) for 1 hour before the addition of LY30 for the indicated 
timepoints and the lysates were subjected to western blot analysis. A noteworthy 
observation here is that pharmacological inhibition of JNK (SP600125) blocked 
LY30-induced upregulation of DR4 (it had no effect on DR5), whereas presence of  
 
  





Figure 29: Abrogation of cell death when pretreated   
with death receptor blocking antibodies  
SHEP-1 cells were preincubated with or without 
monoclonal antibodies blocking DR4 and DR5 
receptors, followed by treatment with respective drugs. 
The apoptotic cells are calculated as a percentage of the 
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Figure 30: Overexpression of the mitochondrial anti-apoptotic protein Bcl-2 
SHEP-1cells transfected transiently with either empty vector control (pc-DNA), 
transfection control (mock) or 1 µg Bcl-2 protein (pc-DNA-Bcl-2) were treated with 
respective drug triggers and analyzed by Crystal violet assay.  Accompanying 
figures showing Western Blot of overexpressed Bcl-2protein and representative 
crystal violet staining. 
 
  







           
          
        
                                            
                  Figure 31: Increase in total protein levels of death receptors 
SHEP-1 cells at ~90% confluence were treated for up to 2 hours 
with LY30 (25 µmol/L) and (A) 100 µg of total protein was 














             Figure  32: Increased expression of surface death receptors 
(A) SHEP-1 cells were treated with or without 25µmol/L LY30 and with or without 
catalase (2000 units/ml) and analyzed for the surface expression of DR4 and using 
PE-conjugated mouse monoclonal anti-human DR4. Non-specific mouse IgG2B was 
used as an isotype control. A representative histogram underscores the involvement 










Figure  32: Increased expression of surface death receptors 
 (B) SHEP-1 cells were treated with or without 25 µmol/L LY30 and with or without 
catalase (2000 units/ml) and analyzed for the surface expression of DR5 and using 
PE-conjugated mouse monoclonal anti-human DR5. Non-specific mouse IgG2B was 
used as an isotype control. A representative histogram underscores the involvement 
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the ERK inhibitor, PD98059, prevented DR5 (had no effect on DR4) up-regulation 
upon LY30 treatment (Figure 33A).  Unlike JNK and ERK inhibitors, the inability of 
the p38 inhibitor, SB202190, to block the effect of LY30 on death receptor 
expression suggested that p38 activation was not a critical signaling event in LY30-
induced TRAIL sensitization (Figure 33A) which is in line with the data in Figure 23 
showing that inhibiting p38 had no effect on cell viability.  These results are indeed 
interesting and hint to a possible differential regulation of the two receptors by the 
MAPKs.   
 
To further substantiate these findings, SHEP-1 cells were transfected with specific 
siRNAs against each of the target genes [si-ERK1, si-ERK2, si-JNK, si-p38] 
following the manufacturer’s protocol.  Cells were then harvested and lysates were 
subjected to Western blotting for verification of the knock down of individual 
proteins.  Indeed, results show very efficient knock down following 72 hours of 
transfection with the respective siRNAs (Figure 33B).  Next, the effect of MAPK 
gene silencing on LY30-mediated upregulation of cell surface DR4 and DR5 was 
evaluated. The most substantial observation is that silencing JNK significantly 
blocked the effect of LY30 on DR4 expression (2.1X increase in surface expression 
in control cells vs 1.5X in JNK silenced cells), whereas neither ERK (1 or 2) nor p38 
silencing had any noticeable effect on DR4 surface expression (Figure 34 A,B).  In 
contrast, the upregulation of DR5 induced by LY30 was completely blocked by 
silencing ERK 1 or 2 (1.4X increase in surface DR5 in control cells vs 0.8-1X in 
siERK cells), while silencing JNK or p38 did not have any effect on DR5 surface 
expression (Figure 34 A, B).  
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Figure 33: The MAPK’s play a significant role in increased death receptor 
expression 
(A)  Cells were treated for 1 hour with LY30 (25µmol/L) in the presence or absence 
of SP600125 (4µmol/L), SB202190 (10µmol/L), or PD98059 (20µmol/L) and the 
lysates subjected to Western blotting for DR4 and DR5.  The relative differences in 
expression were obtained by densitometry and appear as fold increase with 1 being 
the control expression in untreated cells.  
(B) SHEP-1 cells were transfected with 100nM of ERK1, ERK2, JNK, or p38 
SMART pool siRNA as described and total cell lysates were subjected to Western 
blot analysis using anti-ERK, anti-JNK and anti-p38.  β-actin was probed as a 


















Figure 34: Differential regulation of death receptors by MAPK 
 
(A) siRNA transfected cells (siERK, siJNK or sip38) were treated 
with LY30 (25µmol/L) for 2 hours and surface expression of DR4 
was assessed by flow cytometry using PE-conjugated mouse 


























Figure 34 : Differential regulation of death receptors by MAPK 
 
(B) siRNA transfected cells (siERK, siJNK or sip38) were treated 
with LY30 (25µmol/L) for 2 hours and surface expression of DR5 
was assessed by flow cytometry using PE-conjugated mouse 
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Taken together the data obtained can be summarized as a cascade of events that 
begins with H2O2 production by LY30 that phosphorylates MAPKs which inturn is 
responsible for the differential upregulation of TRAIL death receptors – DR4 and 
DR5 in response to LY30 treatment. Surface increase in TRAIL receptors allows 
enhanced caspase 8 processing and amplification. Thus, leading to heightening of 
apoptotic sensitivity of SHEP-1 cells to TRAIL-mediated apoptosis and significantly 
fortifying the potency of the death signaling network. 
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      PART 5 - DISCUSSION 
 
1.   HIGHLIGHTING THE ROLE OF ROS AS A SIGNALING MOLECULE 
1.1 QUERCETIN – THE LEAD COMPOUND OF  LY29 AND LY30 
 
Quercetin is a dietary flavonoid whose role as an anti-cancer agent has been 
established (Cheng et al, 2010; Chou et al, 2010; Vidya Priyadarsini et al, 2010). One 
study on Quercetin that has made observations relevant to the work in this thesis is a 
study by (Nam et al, 2008) showing that Quercetin inhibits migration of and induces 
apoptosis in osteoblasts through the activation of MAPKs. However, the main 
characteristic of Quercetin that popularized it as an anticancer agent is its ability to 
inhibit proteins such as PI3-K, PI4-K and other ATP- requiring kinases as the 
activation of these is associated with tumor cell survival (Nakanishi et al, 1995).  
Quercetin is the lead compound on which the structures of LY29 and LY30 are 
based. Having observed its effect on PI3-K inhibition with an IC50 of 3.8 µM, the 
search was on for analogs of Quercetin which could inhibit PI3-K more specifically 
and effectively. Thus, the substitution of the dihydroxyphenyl group with a 
morpholine moiety was identified and called LY29 which has enhanced specificity to 
inhibit PI3-K more selectively ( IC50 of 1.4 µM) (Vlahos et al, 1994).  This 
inhibitory effect was greatly dependent on the exact structure and any variation 
caused significant decrease in inhibition. Thus, a change such as replacement of the 
morpholine moiety with an amine group as seen in LY30 was sufficient to markedly 
reduce the inhibitory effect on the PI3-K pathway and hence make it a negative 
analogue of LY29. 
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1.2  ROS AS AN INITIATOR OF CELLULAR SIGNALING AND CELL DEATH 
As introduced earlier, ROS is produced in all living organisms as a natural byproduct 
of oxygen metabolism. The critical intracellular redox status maintained by a balance 
between ROS production and cellular antioxidant defense systems is a well studied 
topic. In general, the early school of thought was that ROS which increased 
drastically in response to environmental stress or exposure to chemicals caused 
“oxidative stress” leading to either extensive cellular damage, necrotic cell death or 
carcinogenesis (Ames, 1983; Feig et al, 1994).  Either of which made ROS to be 
considered a deleterious molecule and this had subsequently lead to the belief that 
activation of antioxidant responses that scavenge ROS are always beneficial 
(Bongers et al, 1995; Mantovani et al, 2002).   
 
Shifting from a tumor initiation to a tumor therapy standpoint, the key thing to 
consider is the differences between the various species of ROS and more 
importantly, the delicate balance between them. Some of the early interesting studies 
by (Clement & Stamenkovic, 1996; Pervaiz et al, 1999; Simizu et al, 1996) 
significantly improved our understanding of these molecules. Adding to our 
knowledge were observations that O2
-
derived nonradical species of ROS such as 
intracellular hydrogen peroxide (H2O2) can be produced by either dismutation of 
superoxide or directly in response to various drug triggers. Using several molecular 
approaches, it was shown that a mild increase in this H2O2 acts as an efficient second 
messenger that decreases intracellular pH and creates an ambience favoring cell 
death (Ahmad et al, 2004; Clement et al, 1998; Hirpara et al, 2001; Simizu et al, 
1998). 
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1.3  BASIS FOR LOOKING AT LY30 AS A POSSIBLE ROS PRODUCING COMPOUND 
The ability of polyyphenolic flavonoids to produce ROS as a signal for cell death has 
been of enormous interest. Although there are isolated studies showing ROS 
production as an important precursor for apoptosis induced by Quercetin in some 
tumor cells such as human hepatoma cells (Chang et al, 2006), its anti-apoptotic 
ability is more often associated with its antioxidant properties and its ability to 
scavenge ROS (Chao et al, 2009; Lee et al, 2003; Seufi et al, 2009). However, 
structural changes that were introduced in to LY29 and LY30 while being derived 
from Quercetin could be the basis for their characteristic to produce ROS rather than 
exhibit anti-oxidant properties.  
This study was initiated by preliminary results indicating that the H2O2 produced by 
LY30 and its parent molecule LY29 enhances drug- induced cell death (Poh et al, 
2007; Poh & Pervaiz, 2005).  The time and dose-dependent increase in ROS 
production by LY30 observed by flow cytometric analysis was decreased when ROS 
levels were lowered using the H2O2 scavenger catalase. This was the first evidence 
that confirmed the possible role of ROS, especially H2O2 in signaling by LY30 on 
this system.  Implicating H2O2 and regarding it as a critical regulator required further 
substantiation in terms of the end-point or effect on survival. Thus, it was of 
significance to observe that scavenging of H2O2 using catalase largely abrogated 
LY30-induced amplification of TRAIL signaling in SHEP-1 cells. This is unarguably 
an important part of understanding the signaling cascade initiated by LY30.  The fact 
that TRAIL, unlike LY30, did not produce any increase in CM-H2DCFDA 
fluorescence allowed us to understand that TRAIL is not involved in redox 
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modulation of SHEP-1 cells. As surmised from our previous understanding of LY30, 
it acts like a sensitizer drug that produces H2O2 as a primary signaling molecule to 
create a permissive intracellular environment for apoptosis execution by TRAIL. 
2.  REGULATION OF MAPKs 
2.1  H2O2 AS AN UPSTREAM REGULATOR OF MAPK ACTIVATION 
Upon observing that LY30 produces H2O2 at significantly early time-points, 
contemplating the possible downstream effector pathways that are activated by H2O2 
led to considering the possible role of MAPKs. The evolutionarily conserved MAPK 
pathway was thought to be important for two preliminary reasons. Primarily, the 
knowledge that cancer cells can be sensitized to apoptosis by stress made it logical to 
assume that activation of stress-activated kinases such as MAPKs might play a role. 
Secondly, MAPKs are known ROS-target proteins and the importance of signaling 
for MAPK via H2O2 to elicit a cell death response is represented by the number of 
extensive studies on this topic. In particular, ROS dependent activation of ERK and 
p38 in Wogonin induced apoptosis of breast cancer cells; anti-cancer response 
elicited by gastric cancer cells upon activation of JNK by Glibenclamide; the role of 
ERK and JNK activation in the anti-tumor effect of Thymoquinone in colon cancer 
cells are indeed convincing (El-Najjar et al, 2009; Kim et al, 2009; Qian et al, 2008; 
Ruiz-Ramos et al, 2005).  As mentioned before, the MAPK pathway is one of the 
most conserved redox-sensitive signaling channels and has been shown to be 
involved in the oxidation mediated inactivation of phosphatases, proteins that 
negatively regulate MAPK activation (Bhat & Zhang, 1999; Chen et al, 2009). In 
addition, corroborating the link between ROS and MAPK are data showing that 
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siRNA mediated silencing of mitogen-activated protein kinase (MAPK) 
phosphatase-1 (MKP-1) amplifies H2O2-mediated cell death and alternatively, cells 
overexpressing MKP-1 were refractory to the death inducing effect of H2O2  (Zhou et 
al, 2006).  
 
As seen in the results obtained, the presence of catalase not only inhibited TRAIL 
sensitization, but also blocked LY30-induced MAPK activation and this placed H2O2 
upstream of MAPKs in the cell death circuitry. In addition, although all the three 
MAPKs – ERK, JNK and p38 were activated in response to H2O2 production by 
LY30, what was initially intriguing was that only ERK and JNK inhibitors rescued 
the enhancement of TRAIL-mediated cell death. The role of p38 in TRAIL-mediated 
apoptosis is understood from limited studies that suggest both a pro-apoptotic and an 
anti-apoptotic function. Drugs such as Genistein and SB 203580 have been shown to 
sensitize hepatocellular carcinoma and breast cancer cells to TRAIL via inhibition of 
p38 (Jin et al, 2009; Weldon et al, 2004) while Diosgenin and Lupulone require 
activation of p38 to signal for enhanced TRAIL sensitivity (Lamy et al, 2011; 
Lepage et al, 2011). It’s a noteworthy observation that although p38 was activated 
transiently by H2O2 with the same kinetics as other MAPKs, its importance in 
sensitization by LY30 to TRAIL in SHEP-1 cells is minimal and its activation might 
have a role that has not been studied here.  
 
2.2  SPATIAL REGULATION OF ERK BY PEA-15 
 
Interestingly, ERK is the MAPK that is more often linked to cell survival (Boucher 
et al, 2000; Zelivianski et al, 2003) while activation of JNK and p38 is associated 
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with cell death (Osone et al, 2004; Xia et al, 1995). Like the activation of PI3-K-Akt 
survival pathway, ERK activation has also been shown by many groups to inhibit 
TRAIL- mediated apoptosis. In addition, inhibiting these survival pathways has been 
shown to be the mechanism of action used by many compounds to potentiate drug-
induced apoptosis (Gulati et al, 2006; Kim & Lee, 2007; Tran et al, 2001). However, 
upon observing that ERK acts as a pro-death protein in SHEP-1 cells wherein 
preincubation of cells with a pharmacological inhibitor of the ERK pathway, 
PD98059 infact abrogates enhancement of TRAIL signaling by LY30, the attention 
was turned to studies that indicate ERK as a protein that signals for cell death such as 
those by (Cagnol & Chambard, 2009; Moon et al, 2010).  Corroborating reports 
convincingly show that preincubation of A172 human glioma cells with either 
catalase or with the MEK1/2 inhibitor, UO126 abrogates apoptotic cell death induced 
by extracellular treatment with H2O2 (Lee et al, 2005).  
In this cell system under study, the initial observation that activated ERK is localized 
to the nucleus hinted that along with its activation, its spatial regulation/ subcellular 
compartmentalization may also be altered by treatment with LY30 (Figure 24). As 
mentioned in the introduction, activated ERK has both cytosolic and nuclear 
substrates. This makes the intracellular functional control and substrate accessibility 
partly dependent on its localization. One protein that is cardinal in two relevant 
functions of this study, regulation of ERK and sensitization of tumor cells to TRAIL-
mediated cell death is a novel phosphoprotein PEA-15 (Callaway et al, 2007; 
Formstecher et al, 2001; Siegelin et al, 2008; Whitehurst et al, 2004).  
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The first approach to decipher the function of PEA-15 in this cellular system was to 
look at modifications such as phosphorylation of PEA-15 that could contribute to its 
function. Interestingly, treatment with LY30 induced rapid phosphorylation of PEA-
15 at Ser104 in a H2O2- dependent and sustained manner. From the perspective of 
general protein function and from what is known about PEA-15 from previous 
studies, phosphorylation of PEA-15 at Ser 104 and Ser 116 by PKC and Akt/CamKII 
respectively, stabilizes it and enhances its anti-apoptotic function (Araujo et al, 1993; 
Trencia et al, 2003).  
However, with relation to ERK, when PEA-15 is bound to it in the basal state, 
phosphorylation at Ser104 has been reported to prevent PEA-15 from being able to 
bind to ERK and retain it in the cytosol, thereby increasing its nuclear presence 
(Renganathan et al, 2005). This is suggested in Figure 28 wherein inhibition of PEA-
15 phosphorylation using Bis I prevents ERK nuclear localization.  Since ERK 
exhibits proapoptotic effects in this system, phosphorylation of PEA-15 which 
allows dissociation of PEA-15 from ERK can be looked at as a pro-death signal. 
More importantly, it does seem to appear that PEA-15 is redox- regulated and this 
has not been reported before making it a pursuable interest. Thus, although not 
conclusive, this study on PEA-15 has made an attempt to show that when an 
upstream signal such as H2O2 production by LY30 activates ERK, the subsequent 
translocation of ERK to the nucleus is initiated possibly by a H2O2-mediated and 
PKC-dependent phosphorylation of PEA-15. Also, since one of the upstream 
activators of the ERK MAPK pathway is PKC in some signaling systems, a cross-
talk between the two is perceivable (Schonwasser et al, 1998).  
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Of note, is the observation that Bis I is able to inhibit phosphorylation of PEA-15 
induced by LY30 specifically as compared to another PKC inhibitor Gö6976. This 
observation needed to be explained and a better understanding of characteristics of 
the inhibitors revealed that Gö6976 inhibits most of the conventional and atypical 
isoforms of PKC while Bis I inhibits most conventional and novel PKC isoforms 
(Martiny-Baron et al, 1993). This might point to the fact that phosphorylation of 
PEA-15 by LY30 might require a novel PKC isoform in SHEP-1 cells which might 
be interesting to understand from the view point of PEA-15 regulation. Incidentally, 
the study by (Renault-Mihara et al, 2006) explains a similar situation wherein the 
downstream effect of PEA-15 was preferentially inhibited by BisI and not by 
Gö6976 and further understanding showed the requirement of the novel proapoptotic 
isoform of PKC, PKCδ in inhibiting PEA-15-mediated astrocyte migration.  
 
3.  UPREGULATION OF DR4 AND DR5 ALLOWS FOR INCREASED LIGAND  BINDING 
 
3.1 EFFICIENT TRAIL/INTRINSIC SIGNALING AND DIMINISHED ROLE OF THE 
MITOCHONDRIA/EXTRINSIC PATHWAY 
The observation that single-agent treatment of cells with LY30 does not activate the 
caspase cascade and induce apoptosis ascertains that LY30 is an ideal sensitizer with 
a specific role in aiding recruitment and/or amplifying essential components of death 
 
Inhibitor PKC PKC PKC PKCI PKC PKC PKC PKC PKC PKC 
Bisindolylmaleimide I 0.008 - 0.018 - - 0.21 0.132 5.8 - - 
Gö 6976 0.0023 - 0.006 - - - - - - 0.02 
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receptor signaling pathway in this cellular system.  Although both the initiator 
caspases - caspase 8 and caspase 9 were activated by LY30 + TRAIL treatment 
(Figure 11),  the fact that combined treatment with LY30 and TRAIL allows for 
robust processing of pro-caspase 8 as compared to TRAIL or LY30 alone, prompted 
evaluation of cell viability in the presence of caspase inhibitors.  Pretreatment of 
cells with either the pan-caspase inhibitor Z-VAD-FMK or the caspase 8 tetrapeptide 
inhibitor, Z-IETD-FMK completely blocked the sensitizing effect of LY30 on 
TRAIL signaling. This indicates that augmentation of TRAIL-induced mainly relied 
on caspase 8 activation and this is suggestive of a strong and efficient extrinsic 
signaling pathway in SHEP-1 cells.  
Perhaps, based on this observation, it is also arguable that the disruption of the 
mitochondrial integrity and the consequent release of cytochrome c from the 
mitochondria may only be redundant in this signaling cascade wherein caspase 8 
activation is sufficient to drive cells towards apoptosis. Thus, in order to ascertain 
whether LY30+TRAIL treatment of SHEP-1 cells may (Type 2) or may not (Type 1) 
require death-amplification signaling by the mitochondria (Scaffidi et al, 1998), cells 
were transiently transfected with Bcl-2 to overexpress the protein. As shown in 
Figure 30, overexpression of Bcl-2 has no effect on LY30 enhanced TRAIL-
mediated apoptosis and points to the diminished role played by the mitochondria in 
this signaling system. Understanding this could be of significant clinical relevance as 
this increases the likelihood of using the combination treatment on tumor cells that 
exhibit resistance to apoptosis or are refractory to chemotherapy due to over-
expression of Bcl-2 (Walczak et al, 2000). 
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3.2  ROLE OF ERK AND  JNK IN DEATH RECEPTOR UPREGULATION 
The observation that a short exposure to LY30 is sufficient to trigger increase in the 
cell surface expression (as early as 30 minutes, peaking at 1 hr) of the TRAIL death 
receptors, DR4 and DR5 is particularly interesting and provides a logical explanation 
for the amplification of TRAIL signaling. It also reinforces the pivotal idea that 
increased sensitivity to TRAIL is linked to a straightforward increment in death 
receptors that become available for ligand binding. Having observed that MAPKs are 
redox regulated in this system and taking a clue from studies on ROS-regulation of 
death receptors, it seemed possible that MAPKs and TRAIL receptors may be part of 
the same signaling channel. This interest to explore the link between them was 
pursued using pharmacological inhibitors of MAPKs and corroborated using siRNA-
mediated gene silencing experiments (Figure 34). The resulting data shows 
interesting differential regulation of receptors wherein JNK inhibition abrogated 
increase in DR4 and ERK inhibition abrogated DR5 upregulation in response to 
LY30 in this system.  Indeed, analysis of the kinetics of MAPK activation and DR 
upregulation upon LY30 treatment revealed that JNK and ERK activation peaked 
prior (15-30min; Figure 21) to DR4 and DR5 up-regulation (60 - 120min; Figure 31).  
 The upstream role of JNK has often been described and shown to be important in 
sensitizing cells to extrinsic death receptor signaling. Studies on Ursolic acid, 
Perifosine and methyl-2-cyano-3,12-dioxooleana-1,9-dien-28-oate (CDDO-Me) are 
in line with our findings that JNK is an important regulator of TRAIL signaling. 
Studies on CDDO-Me in human lung cancer cells showed rapidly triggered JNK 
activation before DR5 upregulation and augmented apoptosis induced by TRAIL.
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Similar to the results obtained with LY30, JNK-specific inhibitor SP600125 blocked 
CDDO-Me-induced increases in JNK activation, DR5 up-regulation and caspase-8 
activation (Fu et al, 2010; Prasad et al, 2010; Yue et al, 2006; Zhou et al, 2006; Zou 
et al, 2004). In addition, contrary to the conventional view, a large number of studies 
now highlight the proapoptotic role of ERK, thus implicating it in enhancement of 
TRAIL induced apoptosis. Involvement of ERK activation in mediating DR5 
upregulation by drugs such as Nimbolide, Butein, Gossypol and Piceatannol has 
been elegantly shown to coordinate sensitization of colon carcinoma cells to TRAIL 
(Drosopoulos et al, 2005; Gupta et al, 2010; Kang et al, 2010; Moon et al, 2010; 
Sung et al, 2010).  These reports and the results explained in this thesis underscore 
the critical role of MAPKs in the sensitization of tumor cells to TRAIL-induced 
apoptosis via up-regulation of DR4 and DR5, and could have important implications 
for TRAIL-based therapeutic intervention. At this point, it is reassuring to note that 
the results obtained for receptor upregulation following p38 inhibition is in 
agreement with earlier observations wherein the p38 inhibitor, SB202190 did not 
have any effect on the cell viability of SHEP-1 cells following treatment with LY30 
+ TRAIL (Figure 23) or on total expression of DR4/5 levels (Figure 34). 
4. USE OF TRAIL AS A SINGLE-AGENT TREATMENT OR IN COMBINATION WITH 
OTHER SENSITIZER DRUGS 
4.1   USE OF TRAIL AS A SINGLE-AGENT OR COMBINATION TREATMENT OPTION 
The experimental reports clarifying the differences between various forms of 
recombinant human TRAIL (rhTRAIL) based on its synthesis allowed for a surge in 
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studies focussing on types of rhTRAIL that were shown to be non- hepatotoxic 
(Ganten et al, 2006). As mentioned earlier, one distinguishing characteristic that 
makes TRAIL an attractive therapeutic option is its ability to be more specific 
towards transformed cells (Nicholson, 2000). The only limitation is the observation 
that tumors can become TRAIL-resistant and thus, TRAIL can be considered as an 
effective monotherapy option only in tumors that are not intrinsically resistant to this 
ligand drug. More importantly, since the time and dose of exposure of tumor cells to 
TRAIL is dependent on the extent of TRAIL sensitivity, tumors that are minimally or 
partially responsive to TRAIL require repeated exposure of this drug over an 
extended period of time. This could infact aid in evolving mechanisms of resistance 
to TRAIL-induced apoptosis and thus, hinders the use of TRAIL as a 
monotherapeutic treatment option.  
The concept of using drugs in combination stems from the observations that cancer 
cells have acquired multiple mechanisms for survival and that a single agent may not 
be able to target all of these. In addition, studies indicating that even those single 
agent drugs that show acute promising results may not be able to prevent relapse of 
the tumor are proposing that combination therapies will be more effective in 
overcoming the cell death barriers in tumor cells. TRAIL has been used in 
combination with a plethora of drugs to either resensitize TRAIL-resistant tumor 
cells or to enhance the efficacy of partially sensitive cells to TRAIL-induced 
apoptosis (Finlay et al, 2010). In contrast to monotherapeutic treatment, the hope is 
that combination of TRAIL with a sensitizing drug of relatively low toxicity may 
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also achieve in making a tumor cell hyperresponsive to treatment, thereby allowing 
for reduced time and dose exposure of cells to the drugs.  
4.2     THE SYSTEMIC EFFECT OF ROS MODULATION ON ENHANCED DRUG 
RESPONSE 
Similar to observations made in this study on LY30, ROS has been shown to be an 
important upstream signaling molecule induced by other TRAIL sensitizing drugs 
albeit with differing downstream target proteins. However, for the successful use of 
TRAIL in combination with molecules that can modulate ROS levels, it requires us 
to understand the possible effects of elevating intracellular ROS on both transformed 
and non-transformed cells. Although tailoring ROS levels is being understood to act 
as a primary trigger to activate cell signaling pathways in tumor cells, its parallel 
effect on normal cells is to be studied and considered. Some encouraging data from 
existing mice studies on a panel of ROS-inducing compounds that induce apoptotic 
cell death indicate that they can activate efficient apoptotic signaling and tumor 
regression without significant systemic antagonistic effects.  
Both Resveratrol, a polyphenolic compound and Curcumin, a dietary flavonoid have 
been shown to produce ROS to sensitize tumor cells to TRAIL-mediated cell death.  
In two separate studies on prostate cancer xenografts in nude mice, Resveratrol and 
Curcumin have been observed to promote anti-proliferative, anti-angiogenic and 
anti-metastatic effects with no unfavourable effects on mice health (Ganapathy et al, 
2011; Shankar et al, 2008).  In another interesting study by (Raj et al, 2012), it was 
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observed that treatment of tumor xenografts in mice with Piperlonguminine exerts 
significant anti-tumor effects. This drug was also shown to elevate ROS levels and 
induce apoptotic cell death, in both cancer cells and transformed normal cells. In 
addition, Piperlonguminine does not induce ROS in normal cells or in immortalized 
non-transformed cells and the authors attribute the possible reason for specificity of 
ROS production to the phenotype acquired by tumor cells during the process of 
transformation.   
Having reported the ability of LY compounds to be ROS-generating drugs, other 
related invivo studies on effects of the other LY compound, LY29 on nasopharyngeal 
carcinoma in athymic nude mice shows that this compound is able to markedly 
reduce tumor cell growth without any adverse outcome in the treated group as 
compared to the control group (Jiang et al, 2010). The identical observations seen in 
SCID mice transplanted with human colon cancer and ovarian cancer xenografts 
followed by exposure to LY29 validate these results (Hu et al, 2000; Semba et al, 
2002). As shown in this study on SHEP-1 neuroblastoma cells, treatment with LY30 
prior to addition of TRAIL resulted in induction of ROS which initiates a signaling 
cascade that eventually lowers the proliferation threshold to accelerate activation of 
the apoptotic machinery. Although this study has focussed on observing the invitro 
effects of this drug combination, the observation that other similar ROS-producing 
drugs are well tolerated invivo allows us to make a conjecture that LY30 could also 
be an efficient sensitizer drug for TRAIL-mediated apoptosis under invivo 
conditions. The existing limited number of invivo studies also underscores the need 
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for better understanding of redox-mediated anti-cancer compounds for use in 
combination therapy. 
4.3 OTHER PROTEINS TARGETED BY LY30  
Many of the sensitizing compounds that are shown to potentiate the response of cells 
to drug-mediated apoptosis are pleiotropic in nature. This opens up the possibility 
that drugs like LY30 have multiple direct targets in the cell other than inducing ROS 
production. The possible off-target effect of these sensitizing drugs on non-
transformed cells is another question raised often. In the case of LY30, some related 
studies have shown mTOR, IAP family proteins and Heat shock protein 27 (Hsp 27) 
as it’s target proteins. Since these proteins are generally upregulated during the 
process of transformation and thus differentially expressed in tumor cells, it reiterates 
the likelihood that LY30 may show minimal untoward effect at the systemic level. 
5.  REGULATION OF TRAIL RECEPTOR EXPRESSION 
Factors’ leading to expression of TRAIL receptors at the cell surface has been a topic 
that is studied extensively. It has been observed that expression of these receptors at 
the surface of the cell can occur by receptor clustering without any significant 
increase in total receptor levels, by post-transcriptional regulation or by increase of 
receptors at the transcript level. Mechanisms that contribute to enhanced TRAIL 
signaling in tumor cells and are largely independent of increase in death receptor 
expression include redistribution and clustering of receptors at the cell surface. Drugs 
such as Quercetin and Resveratrol have been shown to facilitate receptor 
redistribution in to lipid rafts, thereby allowing receptors to be expressed on the cell
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surface. The role of LY29 in facilitating death receptors clustering is a mechanism by 
which trimerised receptors are made readily available for ligand binding and thus, 
promoting increase in TRAIL response. 
Many recent studies which did not find a strong correlation between an increase in 
protein expression of TRAIL receptors and with the corresponding mRNA levels 
have validated a role for transcription-independent control of TRAIL receptor 
upregulation. Post-translational modifications such as structural changes that can 
allow for increase in expression of TRAIL receptors have been studied. Possible 
mechanisms such as O-glycolsylation and S-nitrosylation that promote TRAIL 
receptor trimerisation in a panel of tumor cell lines have been reported by (Tang et 
al, 2006; Wagner et al, 2007). 
Transcriptional regulation is the mechanism most often attributed to increase in 
expression of TRAIL receptors by drugs. Since many of the implicated transcription 
factors are activated by upstream signals such as ROS, redox-dependent 
transcriptional control of TRAIL receptors has been shown to be important. Studies 
by (Liu et al, 2004) has shown that p53 overexpression in p53-null lung cancer cells 
leads to enhanced DR4 expression via the intronic p53 binding site on DR4. 
Conversely, inhibiting p53 sufficed to stunt TRAIL mediated apoptosis. In addition, 
studies on the diterpenoid lactone, Andragraphalide has elucidated a mechanism 
involving transcriptional regulation of DR4 by ROS and p53 which further validates 
that DR4 is indeed a p53 target gene (Zhou et al, 2008).  
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Interestingly, C/EBP homologous protein (CHOP) which is induced in response to 
ER stress has been shown to influence expression of TRAIL receptors in response to 
a number of drugs that include Gossypol, Guggulsterone and Cardamonin (Moon et 
al, 2011b; Sung et al, 2010; Yadav et al, 2011). Activated protein-1 (AP-1) is another 
redox-dependent transcription factor formed by homo or hetero dimerization of 
MAPK target genes c-jun and c-fos which has also been shown to be important in 
TRAIL receptor surface upregulation (Guan et al, 2002). Putative binding sites for 
NF-κB, Sp1 and CCAAT-enhancer-binding proteins (C/EBPs) have also been 
identified in the promoter regions of the TRAIL receptors (Moon et al, 2011a; Shetty 
et al, 2005; Su et al, 2008). Although the exact mechanism by which DR4 and DR5 
is expressed on the cell surface in SHEP-1 cells remains to be understood, some 
preliminary observation that requires further validation indicates a possible role for 
regulation at the transcriptional level. If transcriptional regulation of the TRAIL 
death receptors is speculated, it would be of interest to examine the roles of 
transcription factors such as CHOP and AP-1 which are induced in response to 
upstream signals including stress and MAPKs that are relevant to this study on 
LY30.  
6.   NOVEL COMPOUNDS SUCH AS LY30 AS EFFICIENT SENSITIZERS TO CELL 
DEATH 
6.1  LY30 CREATES A TIPPING POINT THAT DECIDES THE FATE OF TUMOR CELLS 
Corresponding to a spur in reports on tumor cells acquiring resistance to TRAIL by 
exhibiting multiple blockades to TRAIL- induced apoptosis, there is also a surge in 
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ongoing studies on small molecule sensitizers to overcome this resistance. However, 
the mechanism of action of different sensitizers varies based on its intracellular target 
proteins and thus, the response of different tumor cells to pretreatment with 
sensitizers followed by TRAIL varies largely based on the cellular background. The 
discovery of a host of small molecule compounds that inhibit one or more survival 
pathways for sensitization included studies on naturally occurring non-related 
compounds such as Curcumin, Sulphoraphane and Withaferin A. These studies 
aimed to target antiapoptotic proteins such as c-FLIP, NF-κB, XIAP which directly 
or indirectly led to an accompanied increase in death receptor expression, thereby 
aiding increased sensitivity to TRAIL.   
On the other hand, the molecule studied in this thesis, LY30 is shown create a 
suitable intracellular environment that primes SHEP-1 cells to augment TRAIL-
induced apoptotic execution. The activation of this molecular signaling network by 
LY30 was not restricted to SHEP-1 cells. It was encouraging to observe that LY30 
amplifies TRAIL response in other tumor cells such as Jurkat leukemia, LnCAP 
prostate carcinoma, T98G glioblastoma and SH-SY5Y neuroblastoma cells. Since 
the cause and extent of TRAIL resistance in these tumor cells are different, the 
efficiency of sensitization is also varied. The observation that LY30 can potentiate 
TRAIL efficiency in varied tumor cells also reiterates the possibility that LY30 could 
activate multiple effector pathways and downstream mechanisms for enhancing 
TRAIL sensitization. However, the central role played by H2O2 production in signal 
initiation could be the common and crucial tipping point in this signaling cascade. 
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6.2  AUGMENTED TRAIL SIGNALING  BY LY30 
This study centered on understanding the molecular mechanism that leads to 
augmentation of TRAIL-induced apoptosis by the sensitizing molecule LY30. It was 
indeed fascinating to observe the result of simultaneous treatment with LY30 and 
TRAIL as compared to treatment with LY30 or TRAIL alone. Using statistical 
methods such as Isobologram analysis and Combination Index (CI), we concluded 
that this combination treatment is super additive or synergistic.  Also, it was 
interesting to see that single agent treatment with LY30 does not reduce cell viability 
in the short-term assay and neither does it decrease the colony forming ability or 
reproliferation potential of SHEP-1 cells. Considering the fact that drug combination 
therapy is most advantageous to use when tumors don’t respond to single agent 
treatment with the initiator molecule makes LY30 an adept sensitizer that doesn’t 
exhibit any indicative toxicity on its own and only creates a suitable mileu for 
accelerating cell death induction by chemotherapeutic agents or other drug triggers 
such as TRAIL.  
As in most studies, a few pursuable leads will always remain at the very end.  It 
would be of significant interest to further understand the role of PEA-15 in this 
system and to decipher how LY30 differentially regulates the two TRAIL receptors – 
DR4 and DR5. How this study has contributed is perhaps in substantiating the idea 
that pharmacological tailoring of redox status in tumor cells could be an efficient 
method of making them sensitive to various drug triggers and thereby enhancing 
apoptotic cell death. 
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In conclusion, having observed that LY30 produces H2O2 in SHEP-1 neuroblastoma 
cells, it was both of heightened interest and significant challenge to decipher the 
signaling cascade initiated by it that makes it an efficient sensitizer to TRAIL. 
However, at every juncture of understanding the hierarchy of LY30 signaling, it was 
assuring to see how the pathway linked an upstream crucial signal such as H2O2 
production to cell-surface regulation of TRAIL receptors – DR4 and DR5 leading to 
heightened sensitivity to TRAIL. The mechanistic signaling of LY30 is represented 
in a schematic flow chart in Figure 35. 
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Figure 35:  Schematic flow chart   
This study elucidates the mechanism of action of LY30 in SHEP-1 cells 
and provides a mechanistic link between H2O2 and enhanced cellular 
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